Podcast appearances and mentions of Jonathan Rosenberg

Mayur Kamat is the chief product officer at N26—a $9 billion neobank serving over 7 million customers in 25 countries—where he leads product, design, data, and research. Prior to N26, Mayur was Head of Product at Binance, growing the crypto exchange to a peak $400 billion valuation. Earlier in his career, he built and scaled products at Google (Gmail Mobile, Hangouts), Microsoft, and travel unicorn Agoda.Learn:1. How to find and focus on the highest-leverage problems2. Why you shouldn't optimize for compensation early in your career3. Why you should optimize for strengths, not weaknesses4. Why you need to decide if you truly want the C-suite path5. Why working at a fintech company creates exceptional PMs6. Strategy = hypothesis × experimentation velocity7. Small, fast wins compound faster than big, slow bets—Brought to you by:• WorkOS—Modern identity platform for B2B SaaS, free up to 1 million MAUs• Paragon—Ship every SaaS integration your customers want• Vanta—Automate compliance. Simplify security.—Where to find Mayur Kamat:• X: https://x.com/5degreez• LinkedIn: https://www.linkedin.com/in/mayur/—Where to find Lenny:• Newsletter: https://www.lennysnewsletter.com• X: https://twitter.com/lennysan• LinkedIn: https://www.linkedin.com/in/lennyrachitsky/—In this episode, we cover:(00:00) Introduction and Mayur's background(04:49) Working at Binance: An inside look(18:18) Career advice for product managers(27:00) PM career paths(33:58) Understanding fintech customers(36:00) Understanding your strengths(44:46) Creating a culture of experimentation(51:14) Hiring and developing top talent(54:50) Building a diverse product portfolio(57:08) Working in high talent density areas(59:43) Personal and professional balance(01:06:32) High-leverage opportunities and decision making(01:14:28) AI tools in the workplace(01:19:14) Failure corner(01:25:11) Lightning round and final thoughts—Referenced:• Binance: https://www.binance.us/• Google: https://about.google/• Microsoft: https://www.microsoft.com/• Agoda: https://www.agoda.com• N26: https://n26.com/• Which companies accelerate PM careers most: https://www.lennysnewsletter.com/p/which-companies-accelerate-your-pm• Which companies produce the best product managers: https://www.lennysnewsletter.com/p/which-companies-produce-the-best• Bezos Says Work-Life Balance is a “Debilitating” Phrase: https://www.investopedia.com/news/bezos-says-worklife-balance-debilitating-phrase/• Maslow's Hierarchy of Needs: https://www.simplypsychology.org/maslow.html• PayPal Mafia: https://en.wikipedia.org/wiki/PayPal_Mafia• Changpeng Zhao on LinkedIn: https://www.linkedin.com/in/cpzhao/• Ray Dalio on LinkedIn: https://www.linkedin.com/in/raydalio/• Porter's five forces: https://en.wikipedia.org/wiki/Porter%27s_five_forces_analysis• Jonathan Rosenberg on X: https://x.com/jjrosenberg• Aura: https://buy.aura.com/• Intercom: https://www.intercom.com/• Palantir: https://www.palantir.com/• Revolut: https://www.revolut.com/• Chime: https://www.chime.com/• Stripe: https://stripe.com/• Dropbox: https://www.dropbox.com/• Alex Algard on LinkedIn: https://www.linkedin.com/in/alexalgard• Hiya: https://www.hiya.com/• Brian Chesky's new playbook: https://www.lennysnewsletter.com/p/brian-cheskys-contrarian-approach• Gemini: https://gemini.google.com/app• Writer: https://writer.com/• Google Hangouts: https://en.wikipedia.org/wiki/Google_Hangouts• Sundar Pichai on LinkedIn: https://www.linkedin.com/in/sundarpichai/• Google Meet: https://meet.google.com/landing• House on Hulu: https://www.hulu.com/series/ef39603f-eb90-4248-8237-f6168d7c1be1• Big Bang Theory on Hulu: https://www.hulu.com/series/9bde5aeb-5297-4290-b173-19a4d59cc11d• Adolescence on Netflix: https://www.netflix.com/title/81756069• The White Lotus on HBO: https://www.hbo.com/the-white-lotus• Robinhood: https://robinhood.com/us/en/• Nikita Bier's post on X about Bible Chat: https://x.com/nikitabier/status/1915252215507210349• Bible Chat: https://apps.apple.com/us/app/bible-chat-daily-devotional/id6448849666?mt=8• Suno: https://suno.com/home• Disfrutar: https://www.disfrutarbarcelona.com/—Recommended books:• StrengthsFinder 2.0: https://www.amazon.com/StrengthsFinder-2-0-Tom-Rath/dp/159562015X• The 5 Types of Wealth: A Transformative Guide to Design Your Dream Life: https://www.amazon.com/Types-Wealth-Transformative-Guide-Design/dp/059372318X—Production and marketing by https://penname.co/. For inquiries about sponsoring the podcast, email podcast@lennyrachitsky.com.—Lenny may be an investor in the companies discussed. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.lennysnewsletter.com/subscribe

Today, we're talking with Mikal Lewis, a Digital Product Executive at Whole Foods who drove hundreds of millions of dollars in revenue over the course of his career. In this episode, Mikal talks about: Why you should absolutely (ethically) cheat to get outsized results for your product His framework that drove a quarter of a billion dollars in additional revenue for Nordstrom's online store How to use four types of luck to optimize for opportunity And, how to build a quiet portfolio so that you can choose your own career moves Links LinkedIn: https://www.linkedin.com/in/mikalfm/ How Google Works by Eric Schmidt and Jonathan Rosenberg: https://www.amazon.com/How-Google-Works-Eric-Schmidt/dp/1455582328 The Law of Shitty Clickthroughs by Andrew Chen: https://andrewchen.com/the-law-of-shitty-clickthroughs/ Pretentiousness: Why it Matters by Dan Fox: https://www.amazon.com/Pretentiousness-Why-Matters-Dan-Fox/dp/156689428X Chapters 00:00 Intro 01:02 Learning Product from Windows to Whole Foods 03:53 The Four Types of Luck by Eric Schmidt 07:30 Applying Type Four Luck to Product 16:53 Breaking into Product Management at Microsoft 22:58 Transforming Nordstrom's Digital Product Experience 34:23 Professional vs. Non-Professional Product Management 37:06 Outro Follow LaunchPod on YouTube We have a new YouTube page (https://www.youtube.com/@LaunchPod.byLogRocket)! Watch full episodes of our interviews with PM leaders and subscribe! What does LogRocket do? LogRocket combines frontend monitoring, product analytics, and session replay to help software teams deliver the ideal product experience. Try LogRocket for free today. (https://logrocket.com/signup/?pdr)

Jonathan Rosenberg joins Brian and Tom to discuss this important phase 3 trial and efficacy and toxicity signals.

This month's book: The Maltese Falcon by Dashiell Hammett Ghost Pains by Jessi Jezewska StevensThe collection of poetry that Eve referred to and didn't end up writing about (yet) is Eating Bread and Honey by Pattiann Rogers Happy PoemsTrillion Dollar Coach by Eric Schmide, Jonathan Rosenberg & Alan EagleOur email: somethingweread@gmail.com (send us questions!) Our instagram: somethingwereadpodNext month's book: Intermezzo by Sally Rooney Closing poem: “October” by Robert Frost Hosted on Acast. See acast.com/privacy for more information.

Exploring AI's Role in Revolutionizing Customer and Employee Experiences in Contact Centers  Shep Hyken interviews Jonathan Rosenberg, Chief Technology Officer and head of AI at Five9. He talks about how contact centers can use generative AI to deliver customer experiences that people love.  This episode of Amazing Business Radio with Shep Hyken answers the following questions and more:    How can companies effectively balance customer self-service with personal interactions in high-stakes situations?  How does AI contribute to transforming contact center agents into brand ambassadors?  Why is empathy important in customer service interactions, and how can AI complement this human trait?  How does the implementation of AI tools impact companies' return on investment?  How does generative AI reduce labor costs in contact centers while maintaining human involvement?   Top Takeaways:     AI is changing the way that contact centers operate. AI-driven tools can handle simple queries and support human employees in answering complex questions. It allows businesses to offer quick, precise help that reduces call and hold times while keeping human agents available for tasks requiring empathy and complex problem-solving.    Self-service options are growing more advanced and popular. Although AI can tackle straightforward and repetitive tasks, humans are necessary for high-stakes or complicated situations due to their ability to understand emotions and contexts more deeply.     AI isn't about replacing human employees but empowering them. It provides agents with insights and recommendations in real time so they can focus on building stronger relationships with customers. With AI tools, agents can support customers more effectively, easily handle complex queries, and even seize upsell opportunities.     Great customer experiences can lead to loyal customers. With AI tools, employees can easily access customer's history of interactions with the brand and get information from a broad knowledge base that can help them offer personalized solutions. When customers feel understood and valued, they are more likely to return and tell others about their positive experiences.     AI is quicker and more cost-effective to implement than ever, and the return on investment from AI in customer service is significant. AI can shorten call handling times and make each interaction more efficient, saving money for the business.     Plus, Shep and Jonathan discuss what happens to companies that are laggards when it comes to adopting AI. Tune in!  Quote:   "Setting up and implementing AI has historically been expensive and prohibitive for businesses. Now, with generative AI, it is quick and easy to get started, and the cost of maintaining it is low."    About:    Jonathan Rosenberg is the Chief Technology Officer and head of AI at Five9. He is responsible for the engineering and operational teams building Five9's Genius AI portfolio.    Shep Hyken is a customer service and experience expert, New York Times bestselling author, award-winning keynote speaker, and host of Amazing Business Radio. Learn more about your ad choices. Visit megaphone.fm/adchoices

Como preparar jovens de 14 a 20 anos para serem agentes de mudança, empreendendo ou liderando empresas capazes de enfrentar os desafios econômicos, sociais, políticos e ambientais da região? Fernanda Caloi, CEO da ONG LALA Brasil, conta a fórmula, que já impactou as vidas de mais de 2.400 pessoas.Links do episódioO site da LALAA página de LinkedIn de Fernanda CaloiLivro "O coach de um trilhão de dólares: O manual de liderança do Vale do Silício", de Eric Schmidt, Jonathan Rosenberg e Alan Eagle Livro “Um mundo de três zeros – A nova economia de zero pobreza, zero desemprego e zero emissões líquidas de carbono” - de Muhamad YunusLivro “Change for Good: An Action-Oriented Approach for Businesses to Benefit from Solving the World's Most Urgent Social Problems” - de Paul KleinLivro “Impacto positivo (Net Positive): Como empresas corajosas prosperam dando mais do que tiram” - de Paul PolmanLivro “A coragem para liderar” - de Brené BrownFilme “Não olhe para cima”, da Netflix A The Shift é uma plataforma de conteúdo que descomplica os contextos da inovação disruptiva e da economia digital.Visite o site www.theshift.info e assine a newsletter

Episode Summary:In this episode, Maribel Lopez speaks with Five9's CTO and Head of AI Jonathan Rosenberg on AI's potential in the Customer Experience (CX) and Contact Center as a Service (CcaaS) space. Currently, customers are often unsatisfied with chatbot communication services at contact centers. However, AI's increasing generative capabilities show potential for exciting future applications.  Key Themes:Maribel and Jonathan begin by discussing the current state of AI in CcaaS, and how many customers are unsatisfied with their experiences with automated calls. Contact centers have long attempted to automate aspects of the CX experience, first with DTMF and later with directed dialogue.Unlike these technologies, generative AI has seen widespread adoption. Consumer familiarity with artificial intelligence will lead to them understanding how to interact with generative AI over the phone. Jonathan and Maribel also discuss their predictions for how AI will impact jobs in at contact centers. Jonathan believes that jobs will change, but they will not disappear. Last, Jonathan defines open platforms and explains how their unique features allow for useful CX capabilities. The future of AI in CX depends on how quickly companies eliminate AI hallucinations. Once models overcome this obstacle, Jonathan predicts that AI will see wide adoption in the CX space. For detailed show notes, navigate using the time stamps below:Follow Jonathan Rosenberg on LinkedIn: https://www.linkedin.com/in/jonathanrosenberg1/Follow Jonathan Rosenberg on X/Twitter: https://x.com/jjrosenberg?lang=en Read Jonathan Rosenberg's articles in the Forbes Technology Council: https://www.forbes.com/councils/forbestechcouncil/people/jonathanrosenberg/ Read the Broken Earth series: https://www.amazon.com/Broken-Earth-Trilogy-Season-Obelisk/dp/031652719X

Chegamos à metade do ano, e com ela uma novidade: a lista de livros para o segundo semestre, uma curadoria de Cristina de Luca e Silvia Bassi para afiar seu cérebro e entender melhor essas mudanças diárias que nos afetam. Quantos livros você quer ler até o final do ano? A nossa lista de 10 sugestões pode ajudar na escolha.Links do episódioO coach de um trilhão de dólares: O manual de liderança do Vale do Silício de Bill Campbell - escrito por Erick Schimdt, Jonathan Rosenberg e Allan Eagle.O playbook de liderança de Bill Campbell - as regras do coach do Vale do Silício, resumidasBrave New Words: How AI Will Revolutionize Education (and Why That's a Good Thing) - escrito por Salman KhanOn the Edge: The Art of Risking Everything - escrito por Natan Silver數位 Plurality: The Future of Collaborative Technology and Democracy - escrito por E. Glen Weyl e Audrey TangMay Contain Lies: How Stories, Statistics and Studies Exploit Our Biases - And What We Can Do About It - escrito por Alex EdmansAI Needs You: How We Can Change AI's Future and Save Our Own - escrito por Verity HardingA geração ansiosa: Como a infância hiperconectada está causando uma epidemia de transtornos mentais - escrito por Jonathan HaidtPensamento eficaz: Como transformar situações cotidianas em resultados extraordinários - escrito por Shane ParrishHow Life Works: A User's Guide to the New Biology - escrito por Philip BallBillionaire, Nerd, Saviour, King - escrito por Anupreeta Das  A The Shift é uma plataforma de conteúdo que descomplica os contextos da inovação disruptiva e da economia digital.Visite o site www.theshift.info e assine a newsletter

Christina Figiel is a highly regarded people and organizational expert with over twelve years of leadership experience at prestigious companies, including McKinsey & Company. She specializes in strategic transformations, operational efficiency, and founder coaching within the European startup ecosystems. Christina is also a leadership coach at IE Business School in Madrid and a mother of two. Multilingual and passionate about empowering individuals and teams, Christina brings expertise in executive coaching, change management, and workshop facilitation. ⁠Christina Figiel on LinkedIn⁠ Book Mentioned: Trillion Dollar Coach: The Leadership Playbook of Silicon Valley's Bill Campbell by Eric Schmidt, Jonathan Rosenberg, and Alan Eagle In this episode of the Resilience Podcast, Brad welcomes Christina Figiel, a leader in organizational transformation and founder coaching. With her extensive experience in coaching and consulting, Christina delves into the essential components of building high-performing teams. She provides a thorough examination of trust, conflictability, and communication, shedding light on how these elements play a pivotal role in team dynamics and overall organizational success. Christina explores the concept of high-performance teams, emphasizing the importance of continuous growth and adaptability. She addresses common challenges such as resistance to change and the need for establishing trust, the ability to handle conflict and effective communication. With actionable insights and strategies, Christina shares her expertise on creating a culture of high performance and well-being, making this episode invaluable for leaders and team members alike. Key Takeaways: Trust Building: Trust is foundational for high-performing teams, relying on consistency, respect, and authenticity. Conflict ability: Embrace conflict as an opportunity for learning and growth; it's essential for a team's progress and resilience. Communication: Effective communication, including deep listening and clear message delivery, is crucial. Work-Life Balance: Founders and leaders must consciously maintain well-being and balance to sustain long-term success. Diverse Team Dynamics: The right mix of behavioral styles and clear roles enhances team functionality and performance. 1. "A high-performing team is something that never stands still. It's something that goes from one learning curve to the next quite naturally." 2. "Trust is not something that is stable; it can go away. But without trust, you're starting from a very limited ability to perform well." 3. "Conflict actually opens a door because it's already there. There's already an elephant in the room... and it just needs all the energy from the team." 4. "If you feel you're over-communicating, you're probably barely just about communicating enough." 5. "Treat yourself kindly today." For more insights into building high-performance teams and maintaining resilience, tune in to the full episode.

Jonathan Rosenberg and a surprise guest discuss comorbidities and treatment-related side effects.

Jonathan Rosenberg gets to grips with the data available for the bladder cohort from the TDXD Destiny pan-tumour cohort.

Drs. Alicia Morgans and Jonathan Rosenberg share their insights into some interesting abstracts from the 2024 ASCO GU symposium: one covering a model to help predict response to neoadjuvant chemotherapy in patients with muscle invasive UC, and another regarding results from the PemCab study of pembrolizumab and cabozantinib in first‑line advanced UC.

Drs. Jonathan Rosenberg and Alicia Morgans share their insights into some late-breaker abstracts presented at the 2024 ASCO GU symposium in San Francisco. The first is a subgroup analysis from EV‑302 with enfortumab vedotin and pembrolizumab, and the other is AMBASSADOR, which looks at adjuvant pembrolizumab in locally advanced and muscle invasive urothelial cancer.

Drs. Alicia Morgans and Jonathan Rosenberg share their insights into therapeutic sequencing in patients with advanced urothelial cancer, reviewing patient selection and timing, options following progression on immunotherapy, and future therapeutic agents such as HER2‑targeted ADCs.

The following episode is also available on YouTube: https://youtu.be/YkUdy7ZvcAg Today's work environment is dynamic. Leadership approaches that worked for decades just aren't as effective today. Chet Lovegren, aka “The Sales Doctor” shares ideas and insights around managing the balance between empathy and accountability in diverse teams.  Chet has had over 11 years of sales and sales leadership experience before starting The Sales Doctor back in 2020 as a way of providing a prescriptive approach to revenue problems and struggling go-to-market strategies. In this episode, you'll learn Why yesterday's leadership doesn't work with today's employees. Why good managers have both empathy and hold their employees accountable. What are the three employee types to watch for, and how to manage them. If you find yourself in need of some coaching for yourself, or your team, don't hesitate to give Hamish a call.  Resources: Arnold - On Netflix Trillion Dollar Coach: The Leadership Playbook of Silicon Valley's Bill Campbell - by Eric Schmidt, Jonathan Rosenberg, Alan Eagle Chet Lovegren on LinkedIn Chet Lovegren on Linktree   Full Funnel Freedom https://fullfunnelfreedom.com Sandler on Instagram https://www.instagram.com/sandler_yyc/  Sandler in Calgary - www.hamish.sandler.com/howtosandler Connect with Hamish Knox on LinkedIn https://www.linkedin.com/in/hamishknox/ Sponsorship or guest inquiries - podcast@fullfunnelfreedom.com

Welcome to episode #920 of Six Pixels of Separation - The ThinkersOne Podcast. Here it is: Six Pixels of Separation - The ThinkersOne Podcast - Episode #920. Alan Eagle is a senior executive communications expert and co-author of the recently published book, Learned Excellence - Mental Disciplines For Leading And Winning From The World's Top Performers. The book delves into the nuances of mental toughness, the intricate balance between nature and nurture, and the pivotal role of effective communication in fostering leadership and excellence. Alan co-wrote the book with Eric Potterat. One of Eric's many accolades is that he served for 10 years as the psychologist for the US Navy SEALs, and was responsible for the mental assessment, selection, development, maintenance and enhancement programs for the SEALs. Alan is no slouch either. He worked for over 16 years as a Managing Director at Google, where he was also the speechwriter for influential Googlers like Eric Schmidt, Jonathan Rosenberg, Marissa Mayer, and Susan Wojcicki. Alan is also the co-author of How Google Works (with Eric Schmidt and Jonathan Rosenberg) and Trillion Dollar Coach - The Leadership Playbook of Silicon Valley's Bill Campbell (also with Schmidt and Jonathan). In a world increasingly polarized and challenging to navigate, Alan addresses how individuals and organizations can stay true to their core values, even as they grow and evolve. He highlights the crucial role of maintaining these values, not just for personal integrity but also for organizational coherence and success. Alan also explores the idea of managing people in an outcome-focused environment. He advocates for a process-oriented approach, emphasizing the journey over the destination. This perspective, he argues, is not just applicable at the corporate level but resonates universally across various levels and types of organizations. Alan offers profound insights into the realms of leadership, communication, and personal development. His experiences and perspectives provide valuable lessons on resilience, the pursuit of excellence, and the art of effective communication, essential for anyone looking to excel in today's dynamic world. Enjoy the conversation... Running time: 57:22. Hello from beautiful Montreal. Subscribe over at Apple Podcasts. Please visit and leave comments on the blog - Six Pixels of Separation. Feel free to connect to me directly on Facebook here: Mitch Joel on Facebook. Check out ThinkersOne. or you can connect on LinkedIn. ...or on Twitter. Here is my conversation with Alan Eagle. Learned Excellence - Mental Disciplines For Leading And Winning From The World's Top Performers. Co-author Eric Potterat. Trillion Dollar Coach - The Leadership Playbook of Silicon Valley's Bill Campbell. How Google Works. Follow Alan on LinkedIn. Follow Alan on X. This week's music: David Usher 'St. Lawrence River'. Takeaways: Mental toughness is essential for performing well under pressure, and it can be developed through practice and training. Excellence is not limited to high-stress situations. It can be achieved in everyday life. Values and identity play a crucial role in achieving excellence, both individually and within a team or organization. Leaders can create a culture of excellence by exemplifying the principles of learned excellence and fostering open communication and trust. In a polarized world, it is important to focus on shared values and create an inclusive environment that respects diverse perspectives.  Core values should be upheld even as a company grows and faces new challenges. Focusing on the process rather than just the outcome leads to better results. Process is a universal truth that can be applied at any level and in any organization. Compelling communications are about understanding what the audience is interested in. Chapters: 00:00 - Introduction and Background 03:06 - The Importance of Mental Toughness 08:26 - The Difference Between High-Stress Situations and Everyday Stress 11:37 - The Role of Nature vs. Nurture in Developing Mental Toughness 14:48 - The Connection Between Excellence and Identity 18:43 - Applying the Principles of Learned Excellence in Personal Life 23:33 - Creating a Culture of Excellence in the Workplace 28:01 - The Role of Communication in Leadership and Excellence 31:46 - Leadership and Excellence in a Changing World 43:46 - Navigating Values in a Polarized World 47:36 - The Value of 'Don't Be Evil' 50:30 - Managing People in an Outcome-Focused World 53:42 - The Universal Truth of Process 57:08 - The Power of Compelling Communications

Harriet and Producer Martin are joined by Northern Ireland Secretary Chris Heaton Harris, to talk about why he doesn't want to talk about the new powersharing deal in Stormont. They are also joined by friend of the show, The Daily Telegraph's Siobhan Connery, to talk about how brilliant it is that we're now checking food before it comes into the UK. We also have Eshaan Akbar providing a Hot & Spicy Take about about libel law and the "meaning" of "words". Thanks to Iain Fraser, Duncan Collins, Jonathan Rosenberg, Derek JanDoyleBand, David Harford and Tony for signing up to our Patreon this week. They're getting ad-free episodes, exclusive videos, bonus podcasts and other things, and you can join them and help us get to a point where we can pay our guests by going to patreon.com/NonCensored and lapping up all that delicious bonus content. Keep your questions coming to the team by emailing noncensoredpodcast@gmail.com. Thanks to Rosie Holt (@RosieIsAHolt), Brendan Murphy (@notmurphy), Eshaan Akbar (@eshaanakbar), Will Sebag-Montefiore (@wsebag), Bethany Black (@bethanyblack.bsky.social) and Ed Morrish. Tickets for Rosie's show, That's Politainment!, are available here. Tickets for Brendan's show, Buffy Revamped, are available here. Will Sebag-Montefiore does a really good podcast called Legitimate Likes that you should listen to.  Bethany Black is doing film reviews on Patreon for the unbeatable price of £2/month.  Show photography by Karla Gowlett (photoperspective.co.uk) and show design by Chris Barker (chrisbarkerprints.co.uk). Music and jingles by Paddy Gervers & Rob Sell (torchandcompass.com). NonCensored is a Lead Mojo production (leadmojo.co.uk). Learn more about your ad choices. Visit megaphone.fm/adchoices

The future of commerce is Video.Listen to Maryam Ghahremani - CEO at Bambuser - in B2B SaaS CEOs!We discussed why the video is the future, the importance of entertainment, finding a pain → solve the pain → build a relationship, Ikigai, and much more.-Timeline:1:25 - Who is Maryam Ghahremani?4:00 - Bambuser's elevator pitch.5:40 - 5 quick ones.7:00 - Video is the future of commerce.15:10 - External question from Julia Söderqvist at Returbo: "How do you see a difference in the adaptiation of the video commerce between different generations, such as boomers and Gen Z?"19:30 - GTM-strategy: Finding a pain → solve the pain → build a relationship.25:30 - The best way to do outreach to Maryam.34:00 - Maryam's book recommendation: Trillion Dollar Coach.36:00 - A favorite life motto: Ikigai38:00 - The top things she would tell her younger self.-The book Maryam recommended:Trillion Dollar Coach - Eric Schmidt, Jonathan Rosenberg, Alan Eagle-Do you want to get more booked meetings and increase your sales?Automate your outreach with LinkedIn, email, phone, and automated personalized video by using Vaam.Try Vaam for free on vaam.io.Follow Josef Fallesen on LinkedIn: https://www.linkedin.com/in/joseffallesen/Follow Vaam on LinkedIn: https://www.linkedin.com/company/vaam-ioFollow Vaam on Youtube: https://www.youtube.com/@vaam.io-Maryam's company Bambuser is the #1 video commerce platform, empowering brands with immediate conversion, feedback and engagement from their audience.Read more about Bambuser on: https://bambuser.com/-The music: Learning - Averro, AROM, Tore Phttps://open.spotify.com/track/5GOQtwi7xTnEoNqHrBOWem?si=4365c043e90e4444 Hosted on Acast. See acast.com/privacy for more information.

Classical Music in America from the Great War through the Cold War.

For virtually every human being, there's a gap between where they are currently, and where they're *capable* of getting. Sometimes that gap can be small (and closing). Sometimes it can feel gigantic, especially without the right work ethic or motivation, mindset, and soft skill set. But bridging that gap between reality and potential is exactly what our latest guest is an expert in.   Jason Ma is the preeminent Chief Mentor of Next-Gen Leaders and CEO of ThreeEQ. With deep expertise in elite college admissions, college life, executive, and parent coaching, Jason has guided and transformed 1:1 the lives of numerous Gen Z and elder leaders from teens to CEOs, while easing legacy and succession planning in wealthy families.    Listen to the full conversation for more on the secrets behind some of the most successful leaders' motivation, how to overcome imposter syndrome even when you do reach your goals, why humility is so important to leadership, and more.   Here's a Glimpse of What You'll Learn:    What drove Jason to become a foremost coach/mentor in addition to hismigrate from tech and global business repertoireto the coaching sector How Jason guides in overcominges the common challenge of motivation — including for kids with ultra-successful parents  Why Jason believes no human being has reached their full potential, plus the importance of “pragmatic humility”  How to teach someone humility  Why it's so important to want to “aggressively learn” and grow How Jason helps others overcome imposter syndrome Why Jason is a “secret weapon” for helping students getting into top universities with stronger, pragmatic emotional, social, and leadership intelligence (“3EQ”) Why mindset is one of the top challenges that CEOs struggle with The two principles that Jason lives by, how that also guides his work, and Jason's definition for what “character” is How Jason's faith has impacted his work and business How Jason is measuring success in his multiple businesses and in his life Several book recommendations from Jason, including more about his own book    Resources Mentioned in This Episode:  ThreeEQ website “What They Don't Teach You at Harvard Business School: Notes from a Street-smart Executive” by Mark H. McCormack “Thriving on Chaos: Handbook for a Management Revolution” by Tom Peters “Trillion Dollar Coach: The Leadership Handbook of Silicon Valley's Bill Campbell” by Eric Schmidt, Jonathan Rosenberg, and Alan Eagle “The Purpose Driven Life: What on Earth Am I Here For?” by Rick Warren Buy a copy of “Lost at CEO: An Entrepreneur's Guide to Strategy” by Carl J. Cox  40 Strategy Contact 40 Strategy Carl J. Cox on LinkedIn  

Discussing the EV-103 Cohort K study, which resulted in the FDA approval of Enfortumab Vedotin + Pembrolizumab FDA Approval in the Cisplatin ineligible advanced urothelial carcinoma patients. In discussion with the lead author, Dr. Jonathan Rosenberg - Chief of Genitourinary Oncology Service at Memorial Sloan Kettering Cancer Center.

Une odyssée entrepreneuriale foudroyante et impressionnante. Marquée par une croissance mensuelle à 20 % et près de 30M€ de revenus annuels, après seulement 2 années d'activité. Les vélos reconditionnés de Upway roulent à l'électrique, mais pas que : Ils carburent aussi à l'ambition de son co-fondateur et CEO Toussaint Wattinne et à l'engagement de ses équipes sur le terrain. Après deux belles carrières chez Uber, Toussaint et son associé Stéphane ont vite convaincu de prestigieux VC de leur confier 25M€… … Avant même qu'Upway ne vende un seul vélo ! Comment les ont-ils convaincus ? En se projetant dans le futur, et ce, sans se fixer de limite, pour s'affranchir des obstacles du quotidien. Avec un objectif, celui de livrer une idée à la hauteur de leur ambition. Désormais, Toussaint est occupé à gérer l'hyper croissance d'Upway. Il reste focus sur son cœur de métier et bosse beaucoup, sans oublier son équilibre pro/perso. Dans cet épisode, on décrypte : La méthode pour définir - et surtout choisir - son idée ; La technique ultime pour bien rédiger son pitch deck ; Comment gérer ses équipes en hyper croissance ; Comment trouver un équilibre vie pro / perso ; Comment convaincre Blaise Matuidi d'investir dans sa boîte… ; … Et de poser (gratuitement) pour sa marque. Ah, et pour aller plus loin, téléchargez le deck qui a permis à Upway de lever 25M€. C'est précieux et c'est cadeau ! Toussaint et sa team vous offrent une super réduction : avec le code “DOIT” profitez de 100€ de réduction sur votre vélo, pour toute commande supérieure à 500€ ! TIMELINE : 00:00:00 - De l'amour du vélo 00:09:30 - Toussaint Wattinne, “origins” 00:14:50 - Uber de 2013 à 2021 : récit & apprentissages 01:07:14 - Upway, les débuts, l'hyper croissance, l'orga interne 02:41:52 - Batailles internes chez Upway et dans la tête de Toussaint 02:48:20 - Les livres

Drs. Rana McKay and Jonathan Rosenberg highlight key advances in genitourinary cancers featured at the 2023 ASCO Annual Meeting, including the THOR study in mUCC, VESPER in muscle-invasive bladder cancer, CONTACT-03 in mRCC, and TALAPRO-2 in mCRPC. TRANSCRIPT  Dr. Rana McKay: Hello, and welcome to the ASCO Daily News Podcast. I'm Dr. Rana McKay, your guest host for the podcast today. I'm a GU medical oncologist at the Morris Cancer Center at the University of California in San Diego and an associate professor at the University of California in San Diego School of Medicine. Joining me today is Dr. Jonathan Rosenberg, the chief of the Genitourinary Oncology Service at the Memorial Sloan Kettering Cancer Center in New York. We'll be discussing practice-changing studies and other key advances in genitourinary cancers that were featured at the 2023 ASCO Annual Meeting.   You'll find our full disclosures in the transcript of this episode, and disclosures of all guests featured on the ASCO Daily News Podcast are available on our transcripts at asco.org/DNpod.  Jonathan, it's great to have you with us today. How are you?  Dr. Jonathan Rosenberg: I'm doing very well. Thanks so much for hosting today.  Dr. Rana McKay: Oh, of course. It's always fun to step back from ASCO and reflect on all the practice-changing and practice-informing studies that were presented.  Dr. Jonathan Rosenberg: Absolutely.  Dr. Rana McKay: Maybe we can dive right in with LBA4619. This is the much-talked-about THOR study of erdafitinib versus chemotherapy in patients with advanced or metastatic urothelial cancer with select FGFR alterations. What are your key takeaways from this study?  Dr. Jonathan Rosenberg: It is indeed a study we've been waiting for, for quite some time, to see the results in the confirmatory study after the accelerated approval of erdafitinib. This is half of the THOR trial. There were 2 cohorts of patients. One cohort were patients who previously received a checkpoint inhibitor randomized to chemotherapy or erdafitinib, and those data were reported at ASCO this year. The other cohort was randomized against a checkpoint inhibitor in patients who have not received a checkpoint inhibitor, and we'll see those data in a future meeting.   The bottom line for the THOR study is that FGFR3 inhibition improved overall survival compared with chemotherapy, and the chemotherapy in this study was a taxane. The overall survival was 12.1 months for erdafitinib compared to 7.8 months for chemotherapy with a hazard ratio of 0.64. This led to the DMC to stop the study and blind the data and cross people over. There was also a PFS advantage. There really weren't a lot of new toxicity signals seen; the usual suspects in terms of mucositis, hyperphosphatemia, diarrhea, dry mouth, and onycholysis.  And so, what it tells us ultimately is that in a patient who's progressed on a checkpoint inhibitor, we can feel comfortable about using erdafitinib knowing it provides a survival advantage in patients who've been previously treated for advanced urothelial cancer and have an FGFR alteration, either an FGFR2 or 3. And hopefully, we'll see more data in the future from the study, maybe not too long in the future from the other part of the study, comparing it to checkpoint inhibition.   Dr. Rana McKay: That's really exciting. I think it's exciting to see the data about the positivity of erdafitinib versus chemotherapy in this context. Looking at the phase 3 data is going to be really important. Looking at the data in the IO naive context is going to be really important. I feel like this sort of reaffirms what we've been doing in clinical practice. But how do you feel that the study is practice-changing?   Dr. Jonathan Rosenberg: I think it gives us reassurance that for these patients, erdafitinib is an appropriate option. There's no randomized data between erdafitinib and other choices, such as sacituzumab, which is also based on an accelerated approval, or enfortumab, which is based on randomized phase 3 trial. But it gives us level-1 evidence. I do wonder whether the comparison against the checkpoint inhibitor may turn out differently, but we'll see. Those data aren't in evidence. And I do think it was interesting that the majority of patients who were enrolled on the trial were PDL-1 low. We'll see what the comparison to a checkpoint inhibitor is like and whether those patients have similar characteristics.  Dr. Rana McKay: Yeah, you're almost kind of selecting for people that were not primed to respond.   Dr. Jonathan Rosenberg: Exactly.   Dr. Rana McKay: Well, that's really exciting, I think. Moving on to localized bladder cancer, Dr. Pfister presented the results of the VESPER trial. That's LBA4507. I think this study was really important. This was a trial that explored dose-dense MVAC with methotrexate, vinblastine, doxorubicin, and cisplatin or gemcitabine-cisplatin as a perioperative chemotherapy for muscle-invasive bladder cancer. I think there's always been some discussion around these regimens and how they pair up against one another. Can you tell us about these data?   Dr. Jonathan Rosenberg: It's a very interesting study. It was designed back when it was felt that we could not give patients neoadjuvant therapy. And it was designed as either a neoadjuvant or adjuvant approach. Although, in reality, almost everybody who was enrolled in the study got neoadjuvant chemotherapy, which I think speaks to the shift in practice over the last 10 to 15 years towards neoadjuvant rather than adjuvant therapy. It's an interesting trial in that it used a duration of chemotherapy for the MVAC regimen, the dose-dense MVAC regimen that we don't usually use, which is 6 cycles. And functionally, about 40% of patients couldn't make it to 6 cycles and had to stop sooner, versus 4 cycles of q3-week gemcitabine and cisplatin.   And what the data show is that the progression-free survival for the entire intent-to-treat population didn't reach significance. But if you looked at the neoadjuvant population only, there was an improvement in progression-free survival as well as overall survival. So, it's sort of a negative positive trial. Negative for the primary endpoint, but positive for key secondary endpoints. They did a very interesting analysis looking at the number of cycles that patients received regardless of arm, but looking at it by arm. And it's clear from that analysis that the more chemotherapy they got, the better they did.   Although, the flaw in that analysis is that the healthier patients are, the more chemotherapy they're able to tolerate, and therefore that may translate to an improved overall survival irrespective of the amount of chemotherapy. And this was not necessarily a pre-specified analysis. I think some of the statisticians were clutching their chests during the report of this trial, having talked to several afterward. On the other hand, it does say to me that for a fit, younger patient, it is important to consider dose-dense MVAC instead of gemcitabine and cisplatin.   I'll also note, reading the publication from the first part of the trial, that it appears that nobody over 70 was enrolled from everything I could tell. And so, I question the validity of the tolerability of the results for the average 75-year-old that I see in my practice. Although age is not a bright line cut-off for anybody in terms of cancer treatment. But my own experience has been that dose-dense MVAC has been harder to tolerate for a lot of patients in their 70s, whereas I think we should feel quite comfortable giving it to patients in their sixties. And if you ask me how many cycles I would give, I probably wouldn't say 6, for dose-dense MVAC, I would probably say 4.   Dr. Rana McKay: Was there a predilection that there was a more aggressive disease like nodal disease or other things to prompt the 6 versus 4?  Dr. Jonathan Rosenberg: I think that they stopped primarily for toxicity reasons, but it wasn't clear to me that it was a disease-based issue. And for the neoadjuvant therapy, everyone was supposed to be clinically node-negative on entry, so that probably wouldn't have explained it.  Dr. Rana McKay: Very exciting. I know that the data were quite provocative, but I think it's always difficult to interpret these sorts of subgroup of subgroup analyses, and there's a lot of bias in why people may get more versus less. And I think trying to reduce these data to clinical practice is going to be really important, as you've stated.  Dr. Jonathan Rosenberg: Rana, I'd also like to talk about some key advances in renal cell carcinoma that were reported at ASCO. Dr. Choueiri presented data on LBA4500, the CONTACT-03 study, which really was the first study of its kind in solid tumors because it addressed a major question in the kidney cancer field and in other fields: Is there a role for immunotherapy rechallenge after progression on immunotherapy? Specifically, the study looked at the efficacy and safety of atezolizumab plus cabozantinib versus cabozantinib alone after progression with prior immune checkpoint inhibitor therapy in metastatic RCC. I'd like you to tell me what you think of this study and the results and how they may affect our practice.   Dr. Rana McKay: Absolutely. This was a critically important study looking at the role of IO post-progression on IO. It was a large phase 3 trial that enrolled patients with clear cell and non-clear cell patients. It actually allowed patients with papillary RCC, unclassified RCC, to enroll in the study, whereas most of these studies are excluding patients with non-clear cell disease. Patients had to have progressed on an immune checkpoint inhibitor given either as adjuvant first line or second line, given either as a single agent or in combination with one of the other combos, whether a VEGF or IO. And patients were randomized one-to-one to receive the combination of atezolizumab plus cabozantinib versus cabozantinib alone. And the dosing of the cabozantinib here is at 60 milligrams in the combination, which is the standard dosing of cabozantinib monotherapy. And the primary endpoints for the trial included PFS and OS.   And in essence, this trial was a completely negative study. The primary endpoint, which was centrally reviewed, rPFS, was negative. The hazard ratio there was 1.03. Overall survival was also negative with a hazard ratio of 0.94. And when you look at the subgroup analyses, there really wasn't any specific subgroup that seemed to derive any benefit, potentially those that had a prior response to an immune checkpoint inhibitor, but in essence, a negative study.   And I think these data are really informative because the discussion at ASCO was conducted by Dr. David Braun, and he actually had conducted a very highly scientific Twitter poll to help guide how to interpret the data and what people do. And from that, about 30% of individuals that completed the poll were actually layering on IO therapy, and continuing IO therapy after somebody progressed on therapy layering in a TKI while keeping the IO backbone going.   And I think what this study proves is that we really don't have any really robust data to guide doing that at the present time. And what we may end up doing is compromising the efficacy of the oral TKI or dose-compromising the oral TKI to try to maintain an ineffective IO. And so, I think at the present time these data, while negative, were truly practice-informing. There are other studies that are looking at this strategy as well. I think one of the criticisms here is that atezolizumab really has not had a great track record in renal cell carcinoma in every single context where it was tested, either alone or in combination. It has not met its primary endpoint and it's not utilized as a treatment in RCC. So, there's some discussion that could this be the fact that this is a PDL-1 inhibitor and that it's atezolizumab. And additionally, I think the thing to point out for is that in the modern era if we look at the cabozantinib control arm, cabozantinib in the refractory setting had a PFS of 10.8 months, which is pretty impressive for a later line PFS, if you will. So, there is another study currently ongoing called the TiNivo-2 study that's looking at tivozanib plus nivolumab versus tivozanib alone in a similar patient population. That trial is enrolling only clear cell patients that had progressed on prior IO. So, I think we'll have additional data, but very, I think, informative. I think this question comes up in a lot in other tumor sites as well because of the broad use of checkpoint inhibitors across hematologic and solid tumor malignancies.   Dr. Jonathan Rosenberg: I think this was the most informative negative study and the most negative trial I've seen in a while as well. But it did highlight the importance of asking these questions where people assume they know the answer already, and in fact, we often don't, and our assumptions are wrong. So, I thought that was fascinating and very well described.    Staying in the kidneys arena. I'd like to talk to you also about the phase 2 KEYNOTE-B61, that's Abstract 4518. It looked at first-line lenvatinib and pembrolizumab across non-clear cell carcinomas. Tell me what you thought of the trial and what your takeaways were.   Dr. Rana McKay: This is an important study. I think the treatment of non-clear cell RCC has lagged. I guess the advances have lagged behind clear cell RCC, and really robust phase 3 randomized studies in people with non-clear cell histologies are very limited. This was a single-arm phase 2, so I think we need to kind of take that for what it's worth, that enrolled patients who had non-clear cell RCC per investigator that had received no prior systemic therapy. So, this was a frontline study, and patients received pembrolizumab plus lenvatinib until disease progression or toxicity.   The study enrolled a very robust 158 patients, which is pretty impressive for a modern-day non-clear cell cohort. We've seen data from nivo-cabo that had gotten presented previously by Dr. Lee. That study was a single institution, about 40 patients or so if you will. The primary endpoint of this study was objective response rate, and the bulk of the patients that were enrolled were papillary RCC. As you would imagine, around 60% of patients were papillary. It did include around 18% with chromophobe RCC. And when we break things down by IMDC risk category, about 44% of patients were favorable-risk disease. I think the percentage of patients who were favorable is higher than if we were to take an all-comer metastatic RCC patient population.   But the objective response rate was pretty impressive at 49% with this combination. The CR rate was right around 5.7%. So, I think certainly a pretty solid signal of efficacy. But again, this is a single-arm phase 2 study. I think what's also really interesting, and I think we have to take subset analyses with a grain of salt if you will, but there were responses that were seen across all histologies. And the prior nivo-cabo study that I had shared with you had previously done a futility analysis for patients with chromophobe RCC, and that cohort actually closed down. And in this study, the response rate for the chromophobe patients, though it wasn't a lot of patients, 29 patients with chromophobia RCC, was around 27.6%, so I think these data are certainly informative. If you look at the waterfall plot, there were some deep responses that were certainly observed, and the bulk of patients had some degree of tumor shrinkage with very little patients that had primary PD.   Dr. Jonathan Rosenberg: It's really provocative. So, are we getting to a point where we might start thinking about randomized trials in the non-clear cell population to try to establish the best standard of care?  Dr. Rana McKay: Well, I think PAPMET2 is currently enrolling patients. That study is looking at the combination of cabozantinib with atezolizumab versus cabozantinib alone for frontline papillary. PAPMET1, which was led by Dr. Pal, I mean, these studies are really magnanimous because it takes all hands on deck to get these patients enrolled because they're few and far between. So, I definitely think we need to be moving in that direction. And I think we need to be moving away from lumping all non-clear cells into one bucket because I think what we're seeing is that, one, the biology of these tumors is very distinct and unique, and they don't all behave the same to any one given therapy. So, we really need to move away from just lumping all non-clear cells into one bucket and try to actually conduct studies for each specific subtype.    Dr. Jonathan Rosenberg: Understood and agree. Let's switch gears for a second and talk about prostate cancer. Can you talk about the data from Abstract 5004, the TALAPRO-2 study of talazoparib and enzalutamide compared to placebo and enzalutamide as a first-line treatment with metastatic CRPC that have HR homologous recombination repair gene alterations?    Dr. Rana McKay: Absolutely. So the TALAPRO-2 study is one of three studies that have looked at the combination of PARP inhibitors with an ARSI in the frontline mCRPC setting. And this trial randomized patients to talazoparib and enzalutamide versus placebo enzalutamide. And again, this was first-line mCRPC. Patients were allowed to have received prior docetaxel or prior abiraterone in the castration-sensitive setting, and the primary endpoint was overall survival.  At GU ASCO this year, we saw the top-line data from TALAPRO-2 first get presented. And what was actually presented at this meeting was the subset of patients that were HRR-mutated only. They had two cohorts: an all-comer cohort that was previously presented, and then now they're presenting the subset of the patients that were HRR-mutated. And I think what we've seen across the board is that the efficacy of PARP inhibitors kind of differs by underlying HRR mutations.     When we look at the entire population of HRR-deficient patients, the study was positive, talazoparib plus enzalutamide resulted in an improvement in rPFS compared to enzalutamide placebo. The hazard ratio there was 0.45. And then when we break things down by selected gene groups, they did this subset analysis in patients with only BRCA1, only BRCA2, only PALB2, only CDK12, ATM CHEK2 if you will. The data are most robust for those patients with a BRCA1/2 alteration with hazard ratios of 0.17, 0.19. Again, this is for rPFS.     But then, when we look at some of these other mutations, like ATM CHEK2, hazard ratios are higher, 0.76, 0.90. So, the effect size really kind of drops off for those non-BRCA1/2 altered HRR genes. But if we look across the different subgroup analyses, the interim OS data for the HR deficient, the time to PSA, time to cytotoxic chemo, all of that favored the combination versus placebo enzalutamide for patients that were HR deficient if we just lumped everybody all together.  Dr. Jonathan Rosenberg: How does this fit into the general landscape around this question with selection versus not selecting for HRR alterations?  Dr. Rana McKay: The data that were presented were for the selected patients, and I think that that's not where the controversy is. I think that the selected patients are the ones that seem to derive the most benefit. It's interesting because in looking at the data from PROpel and the final FDA label based off of the PROpel data, the label is only for BRCA1 and 2 patients and not for all comer HRR. It's even a more restricted label than olaporib monotherapy. So, I think it's going to be interesting. I don't know what the right answer is. I think it's going to be interesting to see how this is going to unfold for TALAPRO-2 and even for MAGNITUDE, if you will, like, how select is the selected population going to be. But at the present time, I think the label is what it is for olaparib plus abiraterone in those BRCA1/2 frontline. My hope is that this population is shrinking because everybody should be getting escalated in the metastatic hormone-sensitive setting, and we shouldn't be having people who are naive to an ARSI in frontline mCRPC.  Dr. Jonathan Rosenberg: Understood and agreed.   Dr. Rana Mckay: Well, thank you so much, Jonathan, for joining me today. It's really been a pleasure kind of going through all of the compelling advances in GU cancers from ASCO. I think it was a really exciting meeting, and thanks for your time. Dr. Jonathan Rosenberg: My pleasure. It's been great to talk to you today.     Dr. Rana Mckay: And thank you to our listeners for your time today. You will find links to the abstracts discussed today in the transcript of this episode. Finally, if you value the insights that you hear on the ASCO Daily News Podcast, please take a moment to rate, review, and subscribe wherever you get your podcast.    Disclaimer:   The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guests' statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.    Follow today's speakers:    Dr. Rana McKay  @DrRanaMcKay  Jonathan Rosenberg  @DrRosenbergMSK    Follow ASCO on social media:     @ASCO on Twitter    ASCO on Facebook    ASCO on LinkedIn      Disclosures:    Dr. Rana McKay:   Consulting or Advisory Role: Janssen, Novartis, Tempus, Exelxis, Pfizer, Bristol-Myers Squibb, Astellas Medivation, Dendreon, Bayer, Sanofi, Merck, Vividion, Calithera, AstraZeneca, Myovant, Caris Life Sciences, Sorrento Therapeutics, AVEO, Seattle Genetics, Telix, Eli Lilly, Pfizer, Bayer, Tempus   Dr. Jonathan Rosenberg:   Honoraria: UpToDate, Medscape, Peerview, Research To Practice, Clinical Care Options, Physician Education Resource, MJH Life Sciences, EMD Serono, Pfizer  Consulting or Advisory Role: Lilly, Merck, Roche/Genentech, AstraZeneca/MedImmune, Bristol-Myers Squibb, Bayer, BioClin Therapeutics, QED Therapeutics, Pharmacyclics, GlaxoSmithKline, Janssen Oncology, Astellas Pharma, Boehringer Ingelheim, Pfizer/EMD Serono, Merck Therapeutics, Immunomedics, Tyra Biosciences, Infinity Pharmaceuticals, Gilead Sciences, Hengrui Pharmamedical, Alligator BioScience, Imvax  Research Funding (Institution): Genentech/Roche, Seattle Genetics, Bayer, AstraZeneca, QED Therapeutics, Astellas Pharma  Patents, Royalties, Other Intellectual Property (Institution): Predictor of platinum sensitivity      

“You probably can't overemphasize the importance of your co-founder relationship,” says Noah Abelson-Gertler, founder coach and former public company CEO, explaining that 50% of startups and scaleups that fail do so due to co-founder relationships. Co-founders have an intimacy that is like marriage without the romance—you experience highs and lows, make major decisions together, you're dependent on each other, and can often spend more time together than you do with your actual spouse. That is why it is so important to be as thorough as possible in getting to know your potential co-founder, asking them every possible question, their strengths and weaknesses, references, how they would respond to every possible scenario, and if you can really see yourself working side-by-side with this person for the next ten years. It is just as important to be honest with yourself, about your motivations, shortcomings, etc.  This is something that Noah wishes he had done more of with his own co-founder before entering into business with each other. But, as he mentions, the only other difference between marriage and co-founder partnerships is that co-founders aren't given the tools and resources couples are given. That's why he encourages all founders to find a coach because you really can't know what it's like until you're in it, and as you scale and succeed, your role constantly changes.  Noah and Brendan also touch upon feelings of imposter syndrome, spurred in part by what Brendan calls “success porn.” Founders feel like they are the only ones who feel the increasing pressure that builds commensurate with success. No one has it all figured out, they agree. And if they think they do, they're likely a sociopath.  Quotes “You probably can't overemphasize the importance of your co-founder relationship. So from the moment that you start looking into becoming a co-founder with somebody, you want to focus as much resource on it as, as you logistically can, you're not going to be able to spend 100% of your time on it, never will. But it's wildly important to the success of your business.” (27:43-28:06 | Noah)  “The most similar relationship that you're going to have in your life to a co-founder relationship is a romantic relationship, bar none. It is wildly intimate, you are dependent upon each other, you spend an immense amount of time with each other, and you're making hard decisions constantly. Now, the difference between these two relationships is, and I talk about this a lot in co-founder coaching, a romantic relationship has a bunch of tools to it, the co-founder relationship does not.” (31:26-31:59 | Noah)  “A common thing that comes up is founders who enter into a co-founder relationship is thinking that they don't need to both better get to know themselves, and constantly work on themselves. So that's an understanding you have to have from the jump. If we're going into this together, we both have to have the humility to look at our shortcomings and look at ways that we can improve.” (35:00-35:21 | Noah)  “If you think about what really moves the needle as… it's the inner person, the soft skills that really often make the difference. Can you organize people well, and you're not going to organize and direct a team. It's like when the parents are fighting at home:..If you're not getting along, and you guys are constantly at odds, and there's tension there, the team's going to sense that in there, as you're creating a divide in your business.” (36:26-Brendan | 37:12 | Brendan) Connect with Brendan Dell: LinkedIn: https://www.linkedin.com/in/brendandell/ YouTube: https://www.youtube.com/c/BrendanDell Instagram: @thebrendandell TikTok: @brendandell39 Buy a copy of Brendan's Book, The 12 Immutable Laws of High-Impact Messaging: https://www.indiebound.org/book/9780578210926    Connect with Noah: Foundersjourney.io Check out Noah's recommended books:   Radical Candor: How to be a Kick-ass Boss without Losing Your Humanity by Kim Scott https://bookshop.org/p/books/radical-candor-be-a-kick-ass-boss-without-losing-your-humanity-kim-scott/8486942?ean=9781250235374   Multipliers: How the Best Leaders Make Everyone Smarter by Liz Wiseman  https://bookshop.org/p/books/multipliers-how-the-best-leaders-make-everyone-smarter-liz-wiseman/7213241?ean=9780062663078   The Trillion Dollar Coach: The Leadership Playbook of Silicon Valley's Bill Campbell by Eric Schmidt, Jonathan Rosenberg and Alan Eagle https://bookshop.org/p/books/el-coach-de-sillicon-valley-lecciones-de-liderazgo-del-legendario-coach-de-negocios-bill-campbell-trillion-dollar-coach-eric-schmidt/7976170?ean=9780062839268 Please don't forget to rate, comment, and subscribe to Billion Dollar Tech on Apple, Spotify, or wherever you listen to podcasts! Use code Brendan30 for 30% off your annual membership with RiverSide.fm  Podcast production and show notes provided by HiveCast.fm

Featuring perspectives from Dr Matthew Galsky, Jonathan Rosenberg, and Dr Arlene Siefker-Radtke, moderated by Dr Elisabeth Heath, including the following topics: •      Integrating Novel Treatment Strategies into the Management of Nonmetastatic Urothelial Bladder Cancer (UBC) — Dr Galsky o   Introduction (00:00) o   Case: A man in his late 70s with superficial transitional cell carcinoma of the bladder after bacillus Calmette-Guérin with positive ureteral washing — Sunil Gandhi, MD (2:38) o   Cases: A man in his early 70s with high-grade papillary muscle-invasive bladder cancer with residual disease after neoadjuvant gemcitabine/cisplatin and cystectomy and a man in his early 80s with pT3N0 high-grade urothelial carcinoma after nephroureterectomy (GFR 40) — Ranju Gupta, MD and Swati Vishwanathan, MD (7:04) o   Faculty presentation: Dr Galsky (13:16) •      Current and Future Front-Line Treatment for Metastatic UBC (mUBC) — Dr Rosenberg o   Cases: A man in his mid 70s with metastatic urothelial carcinoma now on maintenance avelumab after gemcitabine/cisplatin and a man in his early 50s with a history of ulcerative colitis diagnosed with metastatic urothelial carcinoma, including brain involvement — Paul Markowski, MD and Gigi Chen, MD) (23:33) o   Case: A woman in her early 80s with unresectable localized urothelial carcinoma; PD-L1 CPS 5, TMB low — Spencer H Bachow, MD (30:54) o   Faculty presentation: Dr Rosenberg (36:21) •      Selection and Sequencing of Therapy for Relapsed/Refractory mUBC — Dr Siefker-Radtke o   Case: A man in his mid 60s with metastatic bladder cancer and progressive disease on cisplatin/gemcitabine, now receiving sacituzumab govitecan — Priya Rudolph, MD, PhD (46:49) o   Case: A man in his mid 60s with de novo metastatic urothelial bladder cancer now receiving pembrolizumab after gemcitabine/carboplatin (rapid progressive disease, FGFR3 mutation) — Yanjun Ma, MD (51:42) o   Faculty presentation: Dr Siefker-Radtke (56:56) •      Novel Investigational Agents and Strategies in the Treatment of mUBC — Dr Heath o   Case: A man in his late 60s with metastatic urothelial carcinoma, PS 2 — Georges Azzi, MD (1:09:30) o   Cases: A man in his mid 70s with metastatic mixed-histology (urothelial, small cell) bladder cancer who receives pembrolizumab and remains in remission 5 years later and a man in his early 50s with metastatic small cell carcinoma of the bladder who receives cisplatin, etoposide and durvalumab followed by maintenance durvalumab, now NED — Victoria Giffi, MD and Laurie Matt-Amaral, MD, MPH (1:13:48) o   Faculty presentation: Dr Heath (1:19:43) CME information and select publications

In this episode of The Tech Talks Podcast, I am thrilled to welcome Jonathan Rosenberg, the CTO and head of AI at Five9. With over 25 years of experience, Jonathan is a true pioneer in the industry, co-inventing SIP and being named one of the 100 most innovative technologists in the world by Technology Review Magazine. Join us as we dive into Jonathan's passion for technology, his pivotal role in SIP's development, and how it transformed the communications landscape by creating new markets and job opportunities. We'll also explore Five9's innovative AI strategy, including their latest product, Agent Assist, designed to enhance customer service agent productivity and efficacy. As the leading provider of cloud customer service technology, Five9 is at the forefront of AI-powered solutions for customer experience. We'll discuss the impact of AI technologies like ChatGPT and GPT-3 on businesses, brand loyalty, and customer experience. Jonathan will share his thoughts on innovation during economic uncertainty, explaining his mantra: "Be adopters, not innovators." Finally, we'll discuss Five9's new European Research and Development site in Portugal and the challenges their engineering teams are tackling. Jonathan will also share his excitement about the future of technology and where current tech trends are taking us.

Music has long been known as a method of communication and bonding. It has the ability to synchronize our bodies and stimulate neuro-chemicals in the brain that help us feel connected to each other. But can this creation of unity and good happen on a large scale, maybe even an international scale? Can music actually be used to decrease tensions between nations and bring in diplomacy? This question was put to the test in 2008, when the New York Philharmonic gave an unprecedented concert in Pyongyang, North Korea. To learn more about this historic concert and its effects, Christine invited back her favorite Julliard-trained musician and Harvard-trained historian, Dr. Jonathan Rosenberg. The answer may surprise you! www.frostedlens.com https://www.amazon.com/Dangerous-Melodies-Classical-America-through/dp/0393608425

En este episodio profundizamos en las lecciones de Bill Campbell a través del libro "Trillion Dollar Coach" de Eric Schmidt, Jonathan Rosenberg y Alan Eagle. Mi compañero para esta hazaña es Carlos Gómez, CEO y fundador de Vivla, 7R ventures y ex-Googler, donde estuvo 10 años pasando por Dublín, San Francisco, Motorola o Waze. Bill fue probablemente el Coach de más éxito de la historia, trabajó con todo el equipo directivo de Google, fue el coach principal de Apple y Steve Jobs durante más de 15 años, del ex vicepresidente de EEUU Al Gore, de Dick Costolo (ex-CEO de Twitter) o de Sheryl Sanberg (COO de Facebook) entre otros.

Today we had the pleasure of sitting down with the incredible and iconic Shay Cochrane, CEO of Social Squares. We chatted about the LIFE-CHANGING concept of her 16-hour work week. Shay covers her story behind starting the 16-hour work week (hint: it's probably not how or when you expected she started it) and her thoughts behind building and scaling a successful business while only working a couple of days a week. --------------------------------- Show notes:  https://theheartuniversity.com/303-how-to-work-a-16-hour-work-week-with-shay-cochrane --------------------------------- Content Pillars Freebie: www.theheartuniversity.com/pillars --------------------------------- Basecamp: www.basecamp.com/heart Use this link to try it for free!  --------------------------------- My Life in a Book: www.mylifeinabook.com Use code HEART10 for $10 off your first purchase!  --------------------------------- Invitation to Solitude and Silence by Ruth Haley Barton Lost and Founder by Rand Fishkin Traction by Gino Wickman Profit First by Mike Michalowicz  Good to Great by Jim Collins Trillion Dollar Coach by Eric Schmidt, Jonathan Rosenberg, Alan Eagle --------------------------------- Follow along with Shay:  www.instagram.com/shaycochrane www.instagram.com/socialsquares www.socialsquares.com --------------------------------- If you want to connect with us and other listeners in the Heart and Hustle community join our Facebook group here. --------------------------------- PODCAST10 for 10% off anything from The Shop! www.theheartuniversity.com/shop --------------------------------- Follow along: www.instagram.com/mrslindseyroman www.instagram.com/evierupp www.instagram.com/theheartuniversity  

Joining us for Episode 148 is the fascinating George Peppou, Founder and CEO of Vow Food, a cultivated meat company, founded and operated in Sydney. Vow is made up of a multidisciplinary team of scientists, technologists and designers, working together in the relentless pursuit of better food.By making meat with animal cells, and not the animals themselves, Vow is creating the world's most tantalising and unique culinary experiences without compromising on ethics or our planet along the way. Ian and George dive into George's career path so far, from studying Biochemistry and Immunobiology at Sydney University to Founder and CEO of Vow Food. Tune in to hear more on: The effects of the meat industry and food production on the Global greenhouse gas emissions  How Vow as a product is produced and when it will first go to market The investment and growth stages of Vow  Georges business and personal challenges Quick fire round: Book: Trillion Dollar Coach: The Leadership Handbook of Silicon Valley's Bill Campbell, By: Eric Schmidt, Jonathan Rosenberg, Alan Eagle Podcast: Lex Fridman and The Constant News Source: ABC/AFR for local news and The Atlantic App: Vimcal - Lightning-fast calendar for remote work Tech CEO: Elon Musk TV Show: Jerrfey Dahmer on Netflix Ted Talk: Woodwork and a mindfulness practice. George is a member of Summit Community at Innovation Bay.  You can find more at VowFood.com, Twitter or Linkedin. Vow Food is hiring so be sure to keep an eye out on their careers page. See omnystudio.com/listener for privacy information.

Trillion Dollar Coach

Some of the best leadership lessons I've learned have come from conversations I've had with sports legends like Ned Yost on the podcast (you can listen here as he talks about how to build a winning team culture). But there's nothing like learning alongside a friend. That's why I'm glad to have Brad Williams back for this episode of Leading Simple. Join us as we sit down to talk about the lessons on leadership we've picked up on throughout the summer, our hopes for the Lakers, and why magnifying the positive is crucial for any leader.Special thanks to Stadia for sponsoring this month's podcast.Resources ​​Blood in the Garden: The Flagrant History of the 1990s New York Knicks - Chris Herring Extreme Ownership: How U.S. Navy SEALs Lead and Win - Jocko Willink and Lief Babin Discipline Equals Freedom - Jocko Willink  Trillion Dollar Coach: The Leadership Playbook of Silicon Valley's Bill Campbell - by Eric Schmidt, Jonathan Rosenberg, and Alan Eagle  A Beautiful Constraint - Andrew Morgan and Mark Barden Mansfield's Book of Manly Men - Stephen Mansfield Become Your Most Masculine Self - Devotional Not in It to Win It: Why Choosing Sides Sidelines The Church - Andy Stanley Top Gun: Maverick - movie starring Tom Cruise

0:00 Intro.1:34 Start of interview.2:12 Keir's "origin story". He grew up in the Bay Area and went to high school in Oakland where he ran track and got a scholarship to go to Ohio State. After realizing he wasn't going to be an Olympian, he decided to study law at U Penn. When he graduated in 1999, he joined the SEC where, among other matters, he was part of the shareholder proposals taskforce which led him on the path of corporate governance. After 6 years at the SEC, he joined Covington & Burling where he practiced for about 13 years. In his last year at Covington he worked on the Uber investigation, after which he was hired to join the company as Associate General Counsel for Corporate (where he led the IPO, the company's corporate governance and ESG programs). He later got promoted to Deputy GC. He joined Broadridge Financial Solutions as Chief Legal Officer in 2021.5:55 Keir's role on the governance assessment for the Holder Report in 2017 [where his firm recommended that Uber focus on four prevailing themes with regard to taking the following remedial measures: tone at the top, trust, transformation, and accountability]. His headline: "Governance directly and unequivocally impacts value." "For me, Uber is the quintessential example for that." "At that time, Uber was king of the world: the largest and most valuable Unicorn, rapidly expanding around the world, they had radically changed how people got around." "Uber's scandal started with Susan Fowler's blog post (which indicated a culture in need of change) and the #DeleteUber campaign post travel ban fiasco in NYC." "These events set the company into a spiral, where they had to address these governance and cultural issues in order to thrive and survive."13:40 On Silicon Valley's "growth at all costs" and "founder empowerment" culture, and the unique distinctions between private vs public corporate governance practices: "The real question in my mind is has Silicon Valley learned its lesson? Have the VCs learned?" "Here is the truth of it: for every Theranos, Uber or WeWork, there is a Facebook, and let's be very candid here, FB is still very successful - if you were an original investor in FB you have done very well for yourself - despite the company not embracing the best corporate governance practices [and yet FB is still thriving]." "[Despite some of the governance scandals in tech companies] there is certainly more awareness now about how corporate governance can impact value."19:07 On the evolution of corporate governance and the growing influence of institutional investors. Its impact on private venture-backed companies: "There must be a governance transition based on the growing number of investors participating in the company's evolution (particularly if/when the company goes public)."25:15 On the history and focus of Broadridge Financial Solutions.27:50 On the role of technology, Blockchain, Meme Stocks and Proxy Voting. The Delaware Vice-Chancellor Travis Laster Speech at CII: "The Block Chain Plunder: Using Technology to Clean Up Proxy Plumbing and Take Back the Vote." (2016) The SEC's Proposal to Reduce Risks in Clearance and Settlement. "I'm not sure blockchain will be the technological solution that everyone is embracing."33:36 On proxy contests ("the level of proxy contests seems lower than what we would have expected."), and the new SEC rules on universal proxy cards. This rule will start applying this August ("will it meaningful increase the number of proxy contests? It's an open question at this point.")40:30 Keir's thoughts on boardroom diversity, including SB-826 and AB-979 getting struck down in California Courts: "I personally would not read too much into those [court decisions in California] for two reasons: 1) Spinning in the wind  and 2) "the horse has left the barn" on the topic of boardroom diversity." "Investors, employees, customers and the general public all care about the composition of a board from a diversity perspective." 45:05 His thoughts on the SEC's current agenda. "There is no doubt that there is a very pro-enforcement agenda in place right now." "There is a new Sheriff in town." The EY Enforcement Action (where EY had to pay a $100M penalty for employees cheating on CPA ethics exams and misleading investigation). Dissent from Commissioner Hester Pierce.51:13 On the politicization of boards and how companies and boards have to deal with hot (and controversial) social topics. Assembling a group of employees to handle how, when and what should the company address about these issues. "It's an incredibly hard challenge for GCs and other senior executives." "Employees, customers and investors expect you to address these issues." "How you communicate is super important." His view on the "Mission-focused company" approach taken by Coinbase: "For me, that probably means that I will never be a Coinbase customer because I care deeply about the company to whom I give my money." "I think of Procter & Gamble as the gold standard on how to communicate effectively around these thorny questions." 58:04 A book that has greatly influenced his life: The Autobiography of Malcom X, by Malcom X and Alex Haley (1965)59:00- Who were your mentors, and what did you learn from them? Marty Dunn, former Deputy Director and Chief Counsel of the SEC and former partner at OMM and MoFo.David Martin, partner at Covington & Burling. He was his "Dutch uncle" ("someone who is going to be very hard on you privately, but in public will sing your praises.")1:00:35 - Are there any quotes you think of often or live your life by? From Trillion Dollar Coach (biography of Bill Campbell) by Alan Eagle, Eric Schmidt and Jonathan Rosenberg (2019):  “Leadership is not about you, it's about service to something bigger: the company, the team. Bill believed that good leaders grow over time, that leadership accrues to them from their teams. He thought people who were curious and wanted to learn new things were best suited for this. There was no room in this formula for smart alecks and their hubris.”1:02:17 - An unusual habit or an absurd thing that he loves: "Zombie Apocalypse everything!"1:03:04 - The living person he most admires: A lot of people but it's a tie: AOC (on the way she uses social media) and Bill Gates (on his transition from business to making a better world).Keir Gumbs is the Chief Legal Officer of Broadridge Financial Solutions, Inc., where he oversees the legal, compliance and physical security teams. Prior to joining Broadridge, Keir served as Deputy General Counsel and Deputy Corporate Secretary of Uber. Before Uber, Keir was a Partner for nearly a decade at Covington & Burling. Keir's career includes six years of service with the SEC, where, immediately prior to joining Covington & Burling in 2005, he served as Counsel to SEC Commissioner Roel C. Campos. __ You can follow Evan on social media at:Twitter: @evanepsteinLinkedIn: https://www.linkedin.com/in/epsteinevan/ Substack: https://evanepstein.substack.com/__Music/Soundtrack (found via Free Music Archive): Seeing The Future by Dexter Britain is licensed under a Attribution-Noncommercial-Share Alike 3.0 United States License

Featuring perspectives from Drs Yohann Loriot, Elizabeth Plimack and Jonathan Rosenberg, including the following topics: Introduction (0:00) Current and Future Management of Localized Urothelial Bladder Cancer (UBC) (2:59) First-Line Treatment for Patients with Metastatic UBC (mUBC) (28:29) Later-Line Therapeutic Options for Patients with mUBC: Novel Investigational Strategies (47:08) CME information and select publications

Para Lao Tzu "um líder é melhor quando as pessoas mal sabem que ele existe, quando seu trabalho estiver feito, seu objetivo alcançado, e elas dirão: nós mesmos conseguimos." Falar sobre liderança é falar sobre servir. Quais são as bases para uma boa liderança? Será que é mais importante saber os tipos de liderança ou os fundamentos? Nós professores e técnicos de voleibol damos a devida atenção a esse tópico essencial do nosso dia a dia? Nossa conversa de hoje foi com meu amigo Cesar Benatti, membro da comissão técnica da equipe da California State University em Bakersfield, CA, nos Estados Unidos. Seguem as indicações de leitura do nosso convidado. No vídeo alguns livros são apresentados com o título original, mas encontramos todas as traduções em português (exemplares disponíveis no Brasil), com exceção da indicação #6 (apenas em inglês, mas também disponível no Brasil) e os listamos a seguir: #1: James C. Hunter. O monge e o executivo. Sextante, 1989. #2: Mike Krzyzewski. Liderar com o coração. Sextante, 2016. #3: Eric Schmidt, Jonathan Rosenberg, Alan Eagle. O coach de um trilhão de dólares. Planeta Estratégia, 2019. #4: Phil Jackson, Hugh Delehanty. Onze Anéis: A alma do sucesso. Rocco, 2014. #5: Jon Gordon. The no complaining rule: positive ways to deal with negativity at work. John Wiley & Sons, 2008. #6: Shawn Achor. O jeito Harvard de ser feliz: o curso mais concorrido da melhor universidade do mundo (The happiness advantage: the seven principles of positive psychology that fuel success and performance at work). Benvirá, 2012. #7: Daniel Goleman. Inteligência emocional. Objetiva, 1995. #8: Carol Dweck. Mindset: a nova psicologia do sucesso. Objetiva, 2017. #9: James Kerr. Legado: 15 lições de liderança que podemos aprender com o time de rugby All Blacks. Benvirá, 2016. #10: Jocko Willink, Leif Babin. Responsabilidade extrema: como os navy seals lideram e vencem. Alta books: 2021. #11: James Clear. Hábitos Atômicos: um método fácil e comprovado de criar bons hábitos e se livrar dos maus. Alta Life, 2019. #12: Bernardinho. Transformando suor em ouro. Sextante, 2011. #13: Jon Gordon. O poder da liderança positiva. Alta Books, 2018. Siga o Cesar também no Instagram: @cesarfeijaobenatti. Gostou da conversa? Não esqueça de deixar seu like! Inscreva-se no canal! Música de abertura e encerramento: Windy City Long (jingle).

Join Ken & Danille as they talk with commercial broker Jonathan Rosenberg, in this condensed discussion about the commercial real estate market and where it is headed. Is retail dead? Is industry the future?Check out Jon's website for further information on his company: https://levrose.comCheck out Ken's Inner Circle where you can watch additional videos, webinars, and happy hour discussions and ask your questions to Ken. Follow this link: https://kensinnercircle.com/• • •Visit Ken's Bookstore: https://kenmcelroy.com/books/•••ABOUT KEN:Ken is the author of the bestselling books The ABC's of Real Estate Investing, The Advanced Guide to Real Estate Investing, The ABC's of Property Management, and has an upcoming book: "ABCs of Buying Rental Property: How You Can Achieve Financial Freedom in Five Years." Ken is a Rich Dad Advisor. With over two decades of experience in real estate investing, Ken McElroy is passionate about sharing the good life by helping real estate investors grow and prosper. This channel is a place for Ken to discuss numerous topics connected to real estate investing, including finance, budgeting, the entrepreneur mindset, and creating passive income.    Ken offers a wealth of personal experiences, practical advice, success stories, and even some informative setbacks, all presented here to educate and inspire. Whether you're a new or seasoned investor, the information and resources on this channel will set you on a path where you and your investments can thrive.Ken's company: https://mccompanies.com/• DISCLAIMERS: Any information or advice available on this channel is intended for educational and general guidance only. Ken McElroy and KenMcElroy.com, LLC shall not be liable for any direct, incidental, consequential, indirect, or punitive damages arising out of access to or use of any of the content available on this channel. Consult a financial advisor or other wealth management professional before you make investments of any kind. Although Ken McElroy and his affiliates take all reasonable care to ensure that the contents of this channel are accurate and up-to-date, all information contained on it is provided ‘as is.'Ken McElroy makes no warranties or representations of any kind concerning the accuracy or suitability of the information contained on this channel. Any links to other websites are provided only as a convenience and KenMcElroy.com, LLC encourages you to read the privacy statements of any third-party websites.All comments will be reviewed by the KenMcElroy.com staff and may be deleted if deemed inappropriate. Comments which are off-topic, offensive or promotional will not be posted. The comments/posts are from members of the public and do not necessarily reflect the views of Ken McElroy and his affiliates. © 2022 KenMcElroy.com, LLC. All Rights Reserved.#kenmcelroy #recession #mortgagerates

Guest host Dr. Neeraj Agarwal, of the University of Utah Huntsman Cancer Institute and the ASCO Daily News editor-in-chief, discusses key therapeutic advances in mRCC and mUC, as well as new research that proposes periodic scans to monitor patients with mCSPC for disease progression, with Dr. Jeanny-Aragon-Ching of the Inova Schar Cancer Institute.  Transcript:  Dr. Neeraj Agarwal: Hello and welcome to the ASCO Daily News podcast. I'm Dr. Neeraj Agarwal, the director of the Genitourinary Oncology Program, a professor of medicine at the University of Utah Huntsman Cancer Institute, and editor-in-chief of the ASCO Daily News.  My guest today is Dr. Jeanny Aragon-Ching, who is a medical oncologist and the Clinical Program Director of Genitourinary Cancers at the Inova Schar Cancer Institute in Virginia.  Today, we will be discussing key posters in genitourinary (GU) oncology that will be featured at the 2022 ASCO Annual Meeting. Our full disclosures are available in the show notes and disclosures of all guests on the podcast can be found on our transcripts at asco.org/podcast.  Jeanny, it is great to have you on the podcast today.  Dr. Jeanny Aragon-Ching: Thanks, Neeraj. It's a pleasure for me to be here as well.  Dr. Neeraj Agarwal: Jeanny, let's begin with Abstract 4510. This is a trial that represents a growing interest among researchers worldwide in the microbiome and how it is impacted by antibiotics and how it modulates immune checkpoint inhibitor response. Can you tell us about this study?  Dr. Jeanny Aragon-Ching: Thanks, Neeraj, I would be happy to. So, the title of the abstract is, “Characterization of the Microbial Resistome in a Prospective Trial of CBM 588 in Metastatic Renal Cell Carcinoma Offers Mechanism for Interplay Between Antibiotic Use and Immune Checkpoint Inhibitor Activity.”  So, this is an interesting abstract that originated likely from the observation that getting antibiotics while on checkpoint inhibitors typically results in worse outcomes, perhaps because antibiotics can clear the normal gut flora and thereby increase these pathogenic antibiotic-resistant bacteria.  Now, on the other hand, there were some retrospective studies using a live microbial product called CBM 588, which seems to improve outcomes in patients on checkpoint inhibitors and getting antibiotics.  So, the idea, therefore, is that shifting the genes encoding antimicrobial resistance could result in a better checkpoint inhibitor response. So, this Abstract 4510 is a small study conducted by Dr. Nazli Dizman and Dr. Sumanta (Monty) Kumar Pal, and colleagues, and enrolled 29 metastatic clear cell RCC patients with intermediate or poorest disease. And they were stratified into receiving either nivolumab or ipilimumab compared to nivo/IPI with CBM 588.  Now stool samples were collected at baseline in week 12. And they did this whole metagenome sequencing to analyze a stool microbiome composition, and they also looked at the antibiotic resistance genes for the most common classes of antibiotics.  The results showed an astounding improvement in objective responses. So, 58%, for instance, in nivo/IPI and the CBM 588 arm compared to only 20% in the nivo/IPI arm. And it seems like also the antibiotics resistance genes were also decreased in those getting the CBM 588 alongside nivo/IPI. Therefore, responses were improved by shifting the gut microbiome alone. So, these findings were published actually recently by these authors in Nature Medicine. So, in case anyone wants to take a deep dive, it would be a good interesting read for this dataset.  Dr. Neeraj Agarwal: Very interesting, indeed. Jeanny, what is the main message here for our colleagues?  Dr. Jeanny Aragon-Ching: I think, Neeraj, the key takeaway message is that this is a very provocative proof of concept trial that suggests shifting the gut microbiome has the potential to improve responses to checkpoint inhibitors and outcomes. So, this is a very up-and-coming trial and is seen also across the board in other cancers.  Dr. Neeraj Agarwal: Thanks, Jeanny. Moving on to urothelial cancer, there is a poster that I think is a must-see for our colleagues. This is Abstract 4577 titled, “Defining Platinum Ineligible Patients with Metastatic Urothelial Carcinoma.”  Dr. Jeanny Aragon-Ching: So, Neeraj, what can you tell us about this abstract?  Dr. Neeraj Agarwal: So, over the past few years, there has been a tremendous evolution in the treatment landscape for patients with metastatic urothelial carcinoma. For over 40 years the standard of care for these patients has been cisplatin-based chemotherapy.  However, approximately 50% of patients are cisplatin-ineligible, due to underlying comorbidities, and are offered carboplatin as an alternative. So, although the checkpoint inhibitors pembrolizumab and atezolizumab were approved as first-line therapy for these patients in 2017, the U.S. Food and Drug Administration (FDA) has now restricted the use of first-line pembrolizumab to platinum ineligible patients with metastatic urothelial carcinoma.  The challenge we face as oncologists since the FDA restriction is the absence of a formal definition of platinum ineligibility and the inclusion of this definition in the guidelines. So, in Abstract 4577, Drs. Shilpa Gupta and Jonathan Rosenberg, along with the team present an updated consensus definition for platinum ineligibility based on an online survey of 60 genitourinary oncologists in the United States.  Based on the results from this survey, any patient with metastatic urothelial carcinoma, meeting 1 of the following 5 clinical and or laboratory parameters should be considered platinum ineligible, and these are 1 of the following: an ECOG performance status of 3 or more, creatinine clearance of fewer than 30 mils per minute, or peripheral neuropathy of grade 2 or more, or heart failure class of 3 or more—so, this is NYHA heart failure class of 3 or more—and lastly, the combination of performance status of 2 or more, plus a creatinine clearance of less than 30 mils per minute.  Dr. Jeanny Aragon-Ching: Well, this is a timely update, Neeraj. So, what do you think is a key takeaway from this abstract?  Dr. Neeraj Agarwal: These criteria based on simple and easily available clinical and or laboratory parameters will now allow us to readily define platinum ineligibility in our patients with metastatic urothelial carcinoma, which is a need in busy clinics, both in academic and community settings.  So, I think once published and obviously once endorsed by guidelines, we really would like to be able to use this criterion to quickly define platinum ineligibility in our clinics.  Dr. Jeanny Aragon-Ching: Agree. Yeah.  Dr. Neeraj Agarwal: So, Jeanny, let me switch the gears. PSMA testing is a hot topic this year. And there is an abstract that could potentially have an impact on future guidelines, and how we will practice further down the road.  So, I'm referring to the Abstract 5088 titled, “Predictive Value of Extra Prostatic Disease Detection by Preoperative PSMAPET for Biochemical Recurrence-free Survival in Patients with Otherwise Localized Prostate Cancer and Who are Treated with Radical Prostatectomy.”  So, this is a follow-up analysis of a multicenter prospective phase 3 imaging trial. So, could you please tell us more about this abstract where they are using PSMA PET scan in the preoperative localized prostate cancer setting?  Dr. Jeanny Aragon-Ching: Absolutely, Neeraj. So, you may recall that the multicenter prospective phase 3 imaging trial that garnered gallium PSMA approval by the FDA was actually based on this study that looked at the intermediate and high-risk patients with prostate cancer undergoing radical prostatectomy and lymph node dissection, and they underwent prior gallium PSMA PET scanning for pelvic nodal metastases prior to surgery.  So, this was actually previously reported by Dr. Calais and group. Now they are reporting on Abstract 5088 as a post hoc analysis of the same population and group of patients looking for extraprostatic disease. And the final pathology was also correlated to look at nodal disease in these patients in order to predict biochemical recurrence, so they follow these patients for biochemical recurrence occurrence.  So, of the 36% of patients who did undergo radical prostatectomy after they underwent PSMA PET scan, about 41% of them recurred with biochemical recurrence, and 40% of them underwent some kind of salvage therapy or some treatment.  What was very interesting was when they looked at the biochemical recurrence-free survival. It was better in those who were PSMA negative, and that recurrence-free survival was easily about 33 months, compared to only about 7.3 months in those who were PSMA-positive scans.  Furthermore, the ones who had the longest and the highest biochemical recurrence-free survival, intuitively, were those who were node-negative and PSMA PET-negative, so probably not surprisingly. And that rate was about 46 months—close to 4 years. Whereas those who are node-positive on final pathology and their PSMA PET was also positive, they only had about 3 months of biochemical recurrence-free survival.  Dr. Neeraj Agarwal: Very interesting. So, it looks like the PSMA PET scan is predicting biochemical recurrence-free survival in localized prostate cancer settings. So, Jeanny, what is the key takeaway from this trial?  Dr. Jeanny Aragon-Ching: I think, Neeraj, the bottom line is that patients with extraprostatic disease that is detected by their preoperative PSMA PET scan does predict strongly a high risk of biochemical relapse, and this can really be an additional tool that clinicians can use to help inform and guide future therapy.  Dr. Neeraj Agarwal: Thanks, Jeanny. The research on preoperative PSMA testing and its implications on future treatment strategies in the setting is going to be really interesting to watch in the very near future.  Dr. Jeanny Aragon-Ching: Yes, absolutely. I really think we should also discuss Abstract 5072, along those lines, the importance really of radiographic monitoring for disease progression in patients with metastatic hormone-sensitive prostate cancer.  Dr. Neeraj Agarwal: Yes, thanks for reminding and this is Abstract 5072. This is a post hoc analysis of the ARCHES trial, titled, “Radiographic Progression in the Absence of PSA Progression in Patients with Metastatic Hormone-sensitive Prostate Cancer.”  During the last several years, we have seen many of these agents typically given for gastric resistant prostate cancer moving upfront to the castration-sensitive prostate cancer setting. This is especially true for androgen receptor access targeting agents such as abiraterone, enzalutamide, and apalutamide, all being now approved for patients with metastatic castration-sensitive prostate cancer.  What is noteworthy from all these trials, and is reported in Abstract 5072, is the use of imaging studies to evaluate disease progression. So, in Abstract 5072, Dr. Andrew Armstrong and Dr. Arun Azad performed a post hoc analysis of the ARCHES trial to investigate the concordance between radiographic progression and the PSA Progression as defined by PCWG2 criteria, or between radiographic progression and any rise in the PSA above nadir, in patients who were being treated with this novel hormonal therapies, in this case, enzalutamide for metastatic castration sensitive prostate cancer.  And as a quick reminder, ARCHES was a phase 3 trial that showed a significant reduction and radiographic progression-free survival and improved overall survival for patients with metastatic castration sensitive prostate cancer treated with enzalutamide plus androgen deprivation therapy (ADT) versus those treated with placebo plus androgen deprivation therapy.  So, very interestingly, the findings from this study indicate that 67% of patients on the enzalutamide plus ADT arm did not have [Prostate Cancer Clinical Trials Working Group 2 criteria] PCWG2-defined prostate-specific antigen (PSA) progression at the time of radiographic progression. And discordance was present in the ADT-only arm as well, where they found 42% of patients on the ADT-only arm had radiographic progression but did not have PCWG2-defined PSA progression.  Interestingly, this discordance of radiographic disease progression was also seen with any rise in the PSA above nadir. And I personally found this information to be very clinically relevant when we are seeing the majority of patients actually experiencing radiographic disease progression, not experiencing PSA progression at the same time.  Dr. Jeanny Aragon-Ching: Yeah, absolutely. I agree with that, Neeraj. So, very interesting data. So, what do you think is the key takeaway message for the clinicians listening to us?  Dr. Neeraj Agarwal: I'll make the message very simple. I think the message is that patients with metastatic castration-sensitive prostate cancer need to be monitored for disease progression with periodic scans, and PSA monitoring alone is not sufficient in the majority of these patients.  Again, we cannot undervalue the role of periodic imaging studies in these patients so that we can timely diagnose them to have disease progression.  Dr. Jeanny Aragon-Ching: I agree with that.  Dr. Neeraj Agarwal: Jeanny, the last abstract I would like to mention before we wrap up the podcast is Abstract 4509, the results from the phase1 live SPARC 001 study. So, can you please tell us more about this study titled, “Phase-1 Live SPARC 001: The Study of Belzutifan in Advanced Solid Tumors,” which is an update of the renal cell carcinoma cohort with more than 3 years of total follow up?  Dr. Jeanny Aragon-Ching: Thanks, Neeraj. So, while the current therapeutic landscape for patients with metastatic clear cell renal cell carcinoma (RCC) has changed dramatically over the past several years, with significant improvement in patient outcomes. Most patients unfortunately still experience disease progression on current treatments.  So, in-depth molecular profiling of clear cell RCC has revealed recurrent loss of function mutations in VHL in actually greater than 90% of patients. So, the VHL protein, as you will recall, is part of the oxygen-sensing pathway, regulating levels of HIF which is hypoxia-inducible factor protein, it's a transcriptional activator that mediates the response to hypoxic conditions. So, HIF-2α is a key oncogenic driver in RCC.  So, previous data you may recall from the phase-1 Live SPARC 001 trial was designed to evaluate belzutifan so, this was a novel HIF-2α inhibitor which showed durable anti-tumor activity and acceptable safety profile in patients with metastatic clear cell RCC.  So, in Abstract 4509, Drs. Jonasch and Toni Choueiri presented updated results from this trial after more than 3 years of follow-up. Of the 55 patients enrolled 16% of patients remained in treatment. And 62% of patients had discontinued treatment because of, unfortunately, disease progression.  The median progression-free survival (PFS) for the total cohort was 14.5 months. And the overall disease control rate was 80%. Forty percent of patients experienced grade 3 treatment-related adverse events with the most frequent ones being anemia and hypoxia.  There were no great 4 or 5 treatment-related adverse events. And these results, therefore, show that belzutifan monotherapy continues to show a high rate of disease control and a safety profile in a heavily treated population of patients with metastatic RCC. So, it is great to see that there were no new safety signals.  Dr. Neeraj Agarwal: Very nice data indeed. So, Jeanny, what is the key takeaway message here for our listeners?  Dr. Jeanny Aragon-Ching: Yeah, I think the message here is that the use of belzutifan monotherapy continues to show efficacy and safety in patients with metastatic clear cell RCC, which have progressed on multiple prior contemporary therapies, and there are phase 3 trials currently underway.  Dr. Neeraj Agarwal: Jeanny, any final thoughts before we wrap up the podcast today?  Dr. Jeanny Aragon-Ching: Thanks, Neeraj. I think it's a really exciting time to be in genitourinary (GU) oncology, and I'm truly looking forward to seeing some great sessions at the 2022 ASCO Annual Meeting.  Dr. Neeraj Agarwal: Thank you, Jeanny, for sharing your insight with us today. It was a great conversation. And thank you to our listeners for joining us today. You will find links to the abstracts discussed today on the transcript of this episode. Finally, if you value the insights that you hear on the ASCO Daily News podcast, please take a moment to rate, review, and subscribe wherever you get your podcast.    Disclosures:   Dr. Neeraj Agarwal:   Consulting or Advisory Role: Pfizer, Bristol-Myers Squibb, AstraZeneca, Nektar, Lilly, Bayer, Pharmacyclics, Foundation Medicine, Astellas Pharma, Lilly, Exelixis, AstraZeneca, Pfizer, Merck, Novartis, Eisai, Seattle Genetics, EMD Serono, Janssen Oncology, AVEO, Calithera Biosciences, MEI Pharma, Genentech, Astellas Pharma, Foundation Medicine, and Gilead Sciences  Research Funding (Institution): Bayer, Bristol-Myers Squibb, Takeda, Pfizer, Exelixis, Amgen, AstraZeneca, Calithera Biosciences, Celldex, Eisai, Genentech, Immunomedics, Janssen, Merck, Lilly, Nektar, ORIC Pharmaceuticals, crispr therapeutics, Arvinas  Dr. Jeanny Aragon-Ching:   Honoraria: Bristol-Myers Squibb, EMD Serono, Astellas Scientific and Medical Affairs Inc  Consulting or Advisory Role: Algeta/Bayer, Dendreon, AstraZeneca, Janssen Biotech, Sanofi, EMD Serono, AstraZeneca/MedImmune, Bayer, Merck, Seattle Genetics, Pfizer, Immunomedics, Amgen, AVEO, Pfizer/Myovant, Exelixis  Speakers' Bureau: Astellas Pharma, Janssen-Ortho, Bristol-Myers Squibb , Astellas/Seattle Genetics  Travel, Accommodations, Expenses: Dendreon, Algeta/Bayer, Bristol Myers Squibb, EMD Serono, Astellas Pharma  Disclaimer:   The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions.  Guests on this podcast expressed their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.       

Jonathan Rosenberg gives an overview of the current landscape.

Is Russian music “canceled?” What sort of responsibility do musicians have to make their political and moral views known? What relationship do music and politics have with one another? Can they truly be separated? In this episode, Christine speaks about this timely topic with Jonathan Rosenberg, Julliard-trained musician and Harvard-trained historian. Using lessons learned while researching his book, "Dangerous Melodies: Classical Music in America from the Great War through the Cold War," Jonathan explains how learning from the past can greatly inform our present, and help us shape the future we would like to see.

The new musical ¡Americano! tells the true story of Tony Valdovinos, a Dreamer who discovers he is an undocumented immigrant when he attempts to join the Marines. Jonathan Rosenberg, co-author of ¡Americano!, joins us to talk about the journey of bringing the show to New York with hopes of transferring to Broadway. ¡Americano! currently runs until June 19th, 2022 at New World Stages in NYC. This episode is sponsored by Harbinger Theatre and their current production of "Destroying David" by Jason Odell Williams, with final performance dates of April 12th, 13th, 15th, and 16th, 2022 at the Opalka Gallery in Albany. 

In this episode, Jim Barnish joins me and we talk about an alternative to climbing the career ladder. We also talk about how careers no longer follow straight lines; Jim shares how his career didn't follow a traditional straight line either. Jim has spent the last two decades growing tech companies as an entrepreneur, operator and consultant. Jim now runs Orchid Black, a growth services firm complete with growth experts, just like Jim, that share an incredible track record for making technology companies worth so much more.Key TakeawaysWhen considering job opportunities, don't only dwell on the functional aspects of the job but look closely at the company cultureSometimes your dream job isn't your ideal jobDon't underestimate the value of having a coachWhen looking for your ideal role, look beyond the career and personality testsIkigai is a fantastic tool to help find your purpose and ideal roleSuccess is not built on success. It's built on failure. It's built on frustration. Sometimes it's built on catastropheIt is okay to make mistakes, as long as you are learning from themPerseverance and working hard are the basic skills that everyone should developWherever you are on your career or entrepreneurial journey, there is always help availableEven if you are not a project manager, having those skills is importantKey transferable skills are communication, critical thinking, and problem-solvingBeing a team player means that you don't always get the wins yourself, but you help others to achieve those winsResources We discussed the following resources on the show:Ikigai on WikipediaThe Squiggly Career: The No.1 Sunday Times Business Bestseller - Ditch the Ladder, Discover Opportunity, Design Your Career by Helen Tupper and Sarah EllisHow Successful People Lead: Taking Your Influence to the Next Level by John C. MaxwellTrillion Dollar Coach: The Leadership Handbook of Silicon Valley's Bill Campbell by Eric Schmidt, Jonathan Rosenberg, and Alan EagleHow to Win Friends and Influence People by Dale CarnegieHow to Ikigai: Lessons for Finding Happiness and Living Your Life's Purpose (Ikigai Book, Lagom, Longevity, Peaceful Living) by Tim TamashiroConnect with JimListeners can learn more about and connect with Jim by visiting his LinkedIn page or the Orchid Black website.Support the show (https://www.buymeacoffee.com/gunterrichter)

In this episode, Amy chats with Melissa Metheny VP Sales and Account Management in the Retail Industry, and David Koroghlian, Senior Director for Marketing Technology in Financial Services to describe the Lead with Emotional Intelligence leader expectation and focus specifically on leading with Trust and Integrity. Melissa and David share their experience with building trust with clients and their teams and how to lead with integrity, even when this is difficult. LeaderTalks@Acxiom is edited by Levi Gilbert. Show Links If by Rudyard Kipling Essentialism by Greg McKeown Trillion Dollar Coach by Eric Schmidt, Jonathan Rosenberg, and Alan Eagle Extreme Ownership by Jocko Willink

Our guest this week is Michael Sarraille, CEO of the Talent War Group. Mike has served as a Marine Scout Sniper, Navy SEAL where he earned the silver star, 6 bronze stars and a purple heart while on deployments on the global war on terror. He's the founder and CEO of the Talent War Group, the Co-Author of the "Talent War" book, the Board of Director of the VETTED program, a Texas McCombs MBA grad and an expert on talent acquisition. He also is the former principal of Echelon Front, a management consulting firm alongside Jocko WIllink and Leif Babin. We talk through his recruiting story, his philosophy on both leadership and talent and what the special forces community can teach the business community. The books he recommends are: Team of Teams by General Stanley Mchrystal Once an Eagle by Anton Myrer Trillion Dollar Coach by Eric Schmidt, Jonathan Rosenberg, Alan Rosenburg The Talent War Group Website: https://talentwargroup.com/​ A link to buy his book: The Talent War: How special Operations and Great Organizations win on talent

“innovation is where the crazy people have stature”Bill Campbell was a trusted, loved and transformational Executive Coach whose clients included many of the corporate and entrepreneurial titans of the Silicon Valley tech world. Bill exemplified many of the foundational skills of The Helping Conversation including empathy, directness, courage and a feeling of love and loyalty for the people he coached and is viewed by many as one of the true visionaries in the practice of Group Coaching.Alan Eagle, Director of Executive Communications at Google, is the co-author, with Eric Schmidt and Jonathan Rosenberg, of the New York Times bestselling book Trillion Dollar Coach: The Leadership Playbook of Silicon Valley's Bill Campbell which chronicles Bill's coaching of the leaders of companies such as Apple, Google and Microsoft.Prior to his present position, Alan was the communications lead for the Google product team, where he developed speeches and other communications for executives including Eric Schmidt, Jonathan Rosenberg, Marissa Mayer, and Susan Wojcicki. Before joining Google in 2007, Alan held sales and product roles at several Silicon Valley start-ups. Alan holds a Computer Science degree from Dartmouth College and an MBA from The Wharton School.For more information on the book, Trillion Dollar Coach:https://www.slideshare.net/ericschmidt/trillion-dollar-coach-book-bill-campbellTo contact Alan Eagle:https://www.linkedin.com/in/alaneagle/

In this episode we connect with Swati Bhatia, Partner at Goldman Sachs to discuss the leadership principles that shaped the innovative culture of Silicon Valley.  Trillion Dollar Coach, authored by Eric Schmidt, Alan Eagle and Jonathan Rosenberg, showcases the life story of Bill Campbell who coached executives across Apple, Google, LinkedIn and several startups in Silicon Valley and helped drive 10X growth and beyond.  A football coach turned high tech executive, Bill Campbell brought out the best in leaders and teams by building an envelope of trust and creating a team first environment. Hear this episode to learn how you can apply the silicon valley success strategies in your life and business.   

There are more than 2 million companies in the U.S. alone that have at least five employees. That means there are 2 million CEOs in this country, and that you have a 1 in 50 chance of becoming one yourself!Hooman Yazhari is the Co-Founder and Chairman of the Board at Beyond Capital Fund. He is a CEO with international experience and serves on several Boards including Bristow Group and Voyager Aviation. He focuses on change management through the life cycles of distressed companies undergoing transformation. Hooman was previously the CEO of Waypoint, a helicopter-leasing business, and served as General Counsel at CHC Helicopter, the world's largest helicopter operator. And he happens to be the husband of our co-host, Eva Yazhari!"If a leader is only thinking 'what's in it for me,' that's not a sustainable way to lead," says Hooman. "Rather, if a leader thinks: how can I get the best out of this team of people? How can I help them succeed? Well then, the team works like a Swiss watch and the leader looks like an absolute genius."Books mentioned: "Great by Choice" by Jim Collins, and "The Trillion Dollar Coach" by Eric Schmidt, Jonathan Rosenberg, Alan Eagle.Read Hooman's article in The Conscious Investor!For more on the podcast, visit The Beyond Capital Podcast website.

Bill Campbell created billions of dollars of value in Silicon Valley as head of marketing and board director for Apple Inc. and CEO for Intuit and GO Corporation. But, he also created trillions of dollars of shareholder value by coaching Larry Page, Sergey Brin, Eric Schmidt, Jonathan Rosenberg and Sundar Pichai at Google, Steve Jobs at Apple, Brad Smith at Intuit, Jeff Bezos at Amazon, John Donahoe at eBay, Marissa Mayer at Yahoo, Dick Costolo at Twitter, and Sheryl Sandberg at Facebook. This episode reviews the book, The Trillion Dollar Coach, and explains how he worked his magic.

Hey ya'll welcome to the fourth episode of the Cowboy Perspective! In this episode I get to talk with Luke Abbott former owner/CEO of Monterrey Provisions Company, a food distributor that grew 800% over a 9 year period under his direction. Luke has a perspective I truly value and trust...as you will see we do find ourselves on the topic of parenting quit a bit...so if you are raising kids and ever think what the heck should I do...please know your not alone! I am excited to share our discussion with you! Links to and lists of information discussed or mentioned throughout this podcast.... Books mentioned The Five Dysfunctions of a Team by Patrick Lencioni Preparing for Adolescence by Dr. James Dobson Can't Hurt Me by David Goggins Quiet The Power of Introverts in a World That Can't Stop Talking by Susan Cain Trillion Dollar Coach by Eric Schmidt, Jonathan Rosenberg, and Alan Eagle Biographies mentioned - Winston Churchill, Ulysses S. Grant Podcasts Referenced - The Tim Ferris Show (Eric Schmidt - Lessons from a Trillion - Dollar Coach), The GaryVee Audio Experience Luke Abbott - Vdriven (1:25) Introduction to Luke Abbott. (3:54) Tell us who you are, or what you have done, or something that you're really into right now. (5:07) Potential suffering of family relationships when a career begins to take off. (6:19) Growing up in the world of cowboys and the pros and cons of such a childhood; understanding the struggle of maintaining family connections; social media having an effect on relationships. (7:52) Let's talk a little about your favorite book and how that might parallel to leading a team, and that distraction being a major failure as a leader. (14:12) How big did your first team get? (14:59) Bonding with an executive team; building a team; learning how to realize that it isn't always your idea that is executed. (16:17) Confidence in suggestions and leadership. (17:32) Reading vs listening literature and influence on daily life. (19:44) Book: It Can't Hurt Me – David Goggins; influences of books on lifestyle and opinions; acknowledge differences and try to understand social issues. (22:41) Cultural problem of idolizing what the high-powered people do; discussion of press; being yourself; anecdote of childhood teachings. (25:16) Training in comparison to learning. (27:50) What do you feel you gained from the retail side? (34:00) Promoting Vdriven (Luke Abbott) (34:58) Let's discuss Monterrey Provisions a little bit and then also Vdriven. (35:35) Anecdote regarding wife; if you want something, go and do it. (37:27) Discussing the importance of positive imagination in reaching goals and gaining success. (46:15) You seem like a guy who likes numbers, is that true? (46:25) I also know that you do a lot of sales, so you like them both, but which do you lean to between the two? (47:32) Summarizing the journey of Luke Abbott; positive effects of having a partner. (48:19) So tell us a little about Vdriven and what a day looks like for you. (48:45) Importance of large fundraisers. (52:20) Does that have to do with CBD? (53:19) Leadership to distract the employees from the work; spending a lot of time working within the company. (54:35) Analyzing what needs to be done. (55:30) Describing the problems to be solved regarding social issues. How can we facilitate our thinking and discussions in ways that we aren't currently doing because we can't see it? (57:05) So, where does your perspective and entrepreneurial spirit come from? (59:27) Story of Gary Vaynerchuk. (1:00:26) Sub-culture of entrepreneurial spirit. (1:00:50) Talk to me about what you think the value of a dollar or a Bitcoin is. (1:02:33) Do you have much time to want to help? (1:03:56) Discussing parenting and the different ways to parent; trust and vulnerability learned from children can apply to the work environment. (1:06:13) Innate feeling of self-doubt inside everyone; self-confidence as a source of protection. (1:08:10) Letting children learn how to navigate daily life; you don't have to stay out of the social media, you just need to be aware. (1:10:07) The acceleration of a need to have discussions with children at a younger age. (1:11:16) Importance of having the conversations; Dr Dobson as a guide for parenting. (1:12:00) Describes a book about Bill Campbell, a coach to the big names of the business world; everyone has a coach – “you're never truly on the top of the mountain”. (1:15:18) Tells the story of how Neil and Luke came to know each other; emphasis on the importance of human connection and how that can affect life. (1:17:04) Play the long-term game, treat the people right, and you will be better off for it

Together with Eric Schmidt, Google's former chairman and CEO, Jonathan Rosenberg and Alan Eagle are the co-authors Trillion Dollar Coach: The Leadership Playbook of Silicon Valley's Bill Campbell. The trio's first book together, How Google Works, was a New York Times bestseller. Jonathan was a Senior Vice President at Google and is an advisor to the Alphabet management team. He ran the Google product team from 2002 to 2011. Alan has been a director at Google since 2007. Formerly Eric and Jonathan's speechwriter, he currently runs a set of Google's sales programs. You can find out more about Jonathan, Alan, and Eric at: https://www.trilliondollarcoach.com Where Others Won't is recorded at Apollo Studios in downtown Toronto. It is produced and edited by Adam Esker. You contact Cody directly by visiting www.codyroyle.com

Jonathan Rosenberg from The Bball Index joins Tony to preview Grizzlies Pacers! #NBA #Pacers #Grizzlies #basketball Learn more about your ad choices. Visit podcastchoices.com/adchoices